<SEC-DOCUMENT>0001047469-16-012614.txt : 20160427
<SEC-HEADER>0001047469-16-012614.hdr.sgml : 20160427
<ACCEPTANCE-DATETIME>20160427160529
ACCESSION NUMBER:		0001047469-16-012614
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160629
FILED AS OF DATE:		20160427
DATE AS OF CHANGE:		20160427
EFFECTIVENESS DATE:		20160427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mirna Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001527599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				261824804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37566
		FILM NUMBER:		161595361

	BUSINESS ADDRESS:	
		STREET 1:		2150 WOODWARD ST., SUITE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78744
		BUSINESS PHONE:		512-681-5252

	MAIL ADDRESS:	
		STREET 1:		2150 WOODWARD ST., SUITE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78744
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2228438zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg49201_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> MIRNA THERAPEUTICS, INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=174923,FOLIO='blank',FILE='DISK122:[16ZBA1.16ZBA49201]BA49201A.;6',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>MIRNA THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>2150 Woodward Street, Suite&nbsp;100<BR>
Austin, Texas 78744  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF ANNUAL MEETING OF STOCKHOLDERS<BR>
TO BE HELD ON JUNE 29, 2016  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To the Stockholders of Mirna Therapeutics,&nbsp;Inc.: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Annual Meeting of Stockholders, or the Annual Meeting, of Mirna Therapeutics,&nbsp;Inc., a Delaware corporation, or the Company, will be held on Wednesday, June&nbsp;29, 2016 at
8:00&nbsp;a.m. local time at the offices of Latham&nbsp;&amp; Watkins&nbsp;LLP, 885 Third Avenue, New York, New York for the following purposes: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
elect three Class&nbsp;I directors to hold office until the 2019 Annual Meeting of Stockholders or until their successors are elected;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
ratify the selection, by the audit committee of our board of directors, of Ernst&nbsp;&amp; Young&nbsp;LLP as the independent registered public accounting
firm of the Company for its fiscal year ending December&nbsp;31, 2016; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing items of business are more fully described in the proxy statement accompanying this Notice. Only stockholders who owned the Company's common stock at the close of business
on May&nbsp;2, 2016 may vote at the Annual Meeting or any adjournments that take place. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have elected to provide our proxy materials to our stockholders over the internet as permitted by the rules of the U.S. Securities and Exchange Commission. As a result, we are mailing
most of our stockholders a paper copy of the Notice of Internet Availability of Proxy Materials, or the Notice, but not a paper copy of our proxy statement. This process allows us to provide our proxy
materials to our stockholders in a timelier and more readily accessible manner, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials. The
Notice contains instructions on how to access those documents over the internet. The Notice also contains instructions on how to request a paper copy of our proxy materials, including this proxy
statement and a form of proxy card or voting instruction card. All stockholders who have previously requested a paper copy of our proxy materials will continue to receive a paper copy of the proxy
materials by mail. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cordially invited to attend the Annual Meeting in person. Whether or not you plan to attend the Annual Meeting, please vote as soon as possible. You may vote over the internet or
by a toll-free telephone number. If, however, you requested to receive paper proxy materials, then you may vote by
mailing a complete, signed and dated proxy card or voting instruction card in the envelope provided. Please note that any stockholder attending the Annual Meeting may vote in person, even if the
stockholder has already returned a proxy card or voting instruction card. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors recommends that you vote "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the election of the director nominees named in Proposal No.&nbsp;1 of the proxy
statement and "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm as
described in Proposal No.&nbsp;2 of the proxy statement. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>/s/ PAUL LAMMERS<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Paul Lammers, M.D., M.Sc.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Austin,
Texas<BR>
April&nbsp;27, 2016 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=330610,FOLIO='blank',FILE='DISK122:[16ZBA1.16ZBA49201]BC49201A.;6',USER='DNICHOL',CD='26-APR-2016;16:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG49201A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg49201_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG49201_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Question"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>QUESTIONS AND ANSWERS REGARDING THESE PROXY MATERIALS AND THE VOTING PROCESS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Question"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc49201_proposal_no._1_election_of_directors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 1: ELECTION OF DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc49201_proposal_no._1_election_of_directors"><FONT SIZE=2>6</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de49201_proposal_no._2_ratification_of__pro03498"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 2: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de49201_proposal_no._2_ratification_of__pro03498"><FONT SIZE=2>10</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49201_report_of_the_audit_co__dg402260"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49201_report_of_the_audit_co__dg402260"><FONT SIZE=2>11</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di49201_corporate_governance"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CORPORATE GOVERNANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di49201_corporate_governance"><FONT SIZE=2>12</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk49201_certain_relationships_and_related_party_transactions"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk49201_certain_relationships_and_related_party_transactions"><FONT SIZE=2>18</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dm49201_non-employee_director_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NON-EMPLOYEE DIRECTOR COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm49201_non-employee_director_compensation"><FONT SIZE=2>19</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#do49201_executive_officers"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE OFFICERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#do49201_executive_officers"><FONT SIZE=2>22</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dq49201_executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq49201_executive_compensation"><FONT SIZE=2>24</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ds49201_security_ownership_of_certain___sec02525"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ds49201_security_ownership_of_certain___sec02525"><FONT SIZE=2>30</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ds49201_section_16(a)_benefici__ds402038"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ds49201_section_16(a)_benefici__ds402038"><FONT SIZE=2>32</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ds49201_additional_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADDITIONAL INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ds49201_additional_information"><FONT SIZE=2>33</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=868777,FOLIO='blank',FILE='DISK122:[16ZBA1.16ZBA49201]BG49201A.;5',USER='DNICHOL',CD='26-APR-2016;13:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da49201_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>MIRNA THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>2150 Woodward Street, Suite&nbsp;100<BR>
Austin, Texas 78744  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT<BR>
FOR THE ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>TO BE HELD ON JUNE 29, 2016  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement, which includes our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2015, are available at our website at
www.mirnarx.com and at www.proxyvote.com. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49201_questions_and_answers_regardin__que03087"> </A>
<A NAME="toc_da49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  <A NAME="Question"></A>QUESTIONS AND ANSWERS REGARDING THE PROXY MATERIALS<BR>  AND THE VOTING PROCESS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Why am I receiving these proxy materials?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have made these proxy materials available to you on the internet or, upon your request, have delivered paper proxy materials to you,
because the board of directors of Mirna Therapeutics,&nbsp;Inc., or the Company, is soliciting your proxy to vote at the Annual Meeting of Stockholders, or the Annual Meeting, or any adjournments
that take place. The Annual Meeting will be held on Wednesday, June&nbsp;29, 2016 at 8:00&nbsp;a.m. local time at the offices of Latham&nbsp;&amp; Watkins&nbsp;LLP, 885 Third Avenue, New York, New
York. As a stockholder, you are invited to attend the Annual Meeting and are requested to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting
to vote. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


What is included in the proxy materials?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The proxy materials include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> This proxy statement, which includes information regarding the proposals to be voted on at the Annual Meeting, the voting process,
corporate governance, the compensation of our directors and certain executive officers, and other required information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2015; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The proxy card or a voting instruction card for the Annual Meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
proxy materials are being mailed or made available to stockholders on or about April&nbsp;27, 2016. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Why did I receive a Notice of Internet Availability of Proxy Materials, or the Notice, in the mail
instead of a complete set of paper proxy materials?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have elected to provide our proxy materials to our stockholders over the internet as permitted by the rules of the U.S. Securities
and Exchange Commission (the "SEC"). As a result, we are mailing most of our stockholders a paper copy of the Notice, but not a paper copy of the proxy materials. This process allows us to provide our
proxy materials to our stockholders in a timelier and more readily accessible manner, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials.
The Notice contains instructions on how to access
the proxy materials over the Internet, and how to request a paper copy of the proxy materials. All stockholders who have </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=688264,FOLIO='1',FILE='DISK122:[16ZBA1.16ZBA49201]DA49201A.;9',USER='DNICHOL',CD='26-APR-2016;16:39' -->
<A NAME="page_da49201_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>previously
elected to receive a paper copy of our proxy materials will continue to receive a paper copy of the proxy materials by mail until the stockholder terminates such election. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Why did I receive a complete set of paper proxy materials in the mail instead of a Notice of
Internet Availability of Proxy Materials?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are providing stockholders who have previously requested to receive paper copies of the proxy materials with paper copies of the proxy materials instead of the Notice. If you would
like to reduce the environmental impact and the costs incurred by us in printing and distributing the proxy materials, you may elect to receive all future proxy materials electronically via email or
the internet. To sign up for electronic delivery, please follow the instructions provided with your proxy materials and on your proxy card or voting instruction card. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Who can vote at the 2015 Annual Meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on May&nbsp;2, 2016 (the "Record Date") will be entitled to vote at the Annual
Meeting. As of April&nbsp;20, 2016, there were 20,830,555 shares of common stock outstanding and entitled to vote. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stockholder of Record: Shares Registered in Your Name  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, at the close of business on the Record Date, your shares were registered directly in your name with our transfer agent, American
Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you
plan to attend the Annual Meeting, please vote as soon as possible by completing and returning the enclosed proxy card or vote by proxy over the telephone or on the internet as instructed below to
ensure your vote is counted. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Beneficial Owner: Shares Registered in the Name of a Broker or Bank  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, at the close of business on the Record Date, your shares were not held in your name, but rather in an account at a brokerage firm,
bank, dealer or other similar organization, then you are the beneficial owner of shares held in "street name" and these proxy materials are being forwarded to you by that organization. The
organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other
agent how to vote the shares in your account. You are also invited to attend the Annual Meeting. However, because you are not the stockholder of record, you may not vote your shares in person at the
Annual Meeting unless you request and obtain a valid proxy from your broker or other agent. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


What proposals are scheduled for a vote?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are two proposals scheduled for a vote at the Annual Meeting:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Proposal No.&nbsp;1&#151;To elect three Class&nbsp;I directors to hold office until the 2019 Annual Meeting of Stockholders
or until their successors are elected; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Proposal No.&nbsp;2&#151;To ratify the selection, by the audit committee of our board of directors, of Ernst&nbsp;&amp;
Young&nbsp;LLP as the independent registered public accounting firm of the Company for the fiscal year ending December&nbsp;31, 2016. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=66848,FOLIO='2',FILE='DISK122:[16ZBA1.16ZBA49201]DA49201A.;9',USER='DNICHOL',CD='26-APR-2016;16:39' -->
<A NAME="page_da49201_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


How do I vote?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For Proposal No.&nbsp;1, you may either vote "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" all nominees to the board of
directors or you may "</FONT><FONT SIZE=2><B>WITHHOLD</B></FONT><FONT SIZE=2>" your vote for any nominee you specify. For Proposal No.&nbsp;2, you may either vote
"</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" or "</FONT><FONT SIZE=2><B>AGAINST</B></FONT><FONT SIZE=2>" or you may abstain from voting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
procedures for voting are as follows: </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stockholder of Record: Shares Registered in Your Name  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy by telephone or internet or by mail.
Whether or not you plan to attend the Annual Meeting, please vote as soon as possible to ensure your vote is counted. You may still attend the Annual Meeting and vote in person even if you have
already voted by proxy.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> To vote in
person.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;You may attend the Annual Meeting and we will give you a ballot when you arrive. If you need directions to the meeting, please
visit http://investor.mirnarx.com/events.cfm.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> To vote by proxy by telephone or
internet.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If you have telephone or internet access, you may submit your proxy by following the instructions provided in the Notice, or
if you received paper proxy materials by mail, by following the instructions provided with your proxy materials and on your proxy card or voting instruction card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> To vote by proxy by
mail.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If you received paper proxy materials, you may submit your proxy by mail by completing and signing your proxy card and mailing it
in the enclosed envelope. Your shares will be voted as you have instructed. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Beneficial Owner: Shares Registered in the Name of Broker or Bank  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a beneficial owner of shares registered in the name of your broker, bank, dealer or other similar organization, you should
have received a proxy card and voting instructions with these proxy materials from that organization rather than from us. Simply complete and mail the proxy card to ensure that your vote is counted.
Alternatively, you may vote by telephone or over the internet as instructed by your broker or other agent. To vote in person at the Annual Meeting, you must obtain a valid proxy from your broker or
other agent. Follow the instructions from your broker or other agent included with these proxy materials, or contact your broker or bank to request a proxy form. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Can I vote my shares by completing and returning the Notice?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No. The Notice will, however, provide instructions on how to vote by telephone, by internet, by requesting and returning a paper proxy
card or voting instruction card, or by submitting a ballot in person at the Annual Meeting. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


How many votes do I have?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On each matter to be voted upon, you have one vote for each share of the Company's common stock you own as of the Record Date. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


What if I return a proxy card but do not make specific choices?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you return a signed and dated proxy card without marking any voting selections, your shares will be voted
"</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the election of each nominee for director (Proposal No.&nbsp;1) and "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the ratification of
the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as the independent registered public accounting firm of the Company for the fiscal year ending December&nbsp;31, 2016 (Proposal No.&nbsp;2). If any
other matter is properly presented at the Annual Meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares in his or her discretion. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=209401,FOLIO='3',FILE='DISK122:[16ZBA1.16ZBA49201]DA49201A.;9',USER='DNICHOL',CD='26-APR-2016;16:39' -->
<A NAME="page_da49201_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Who is paying for this proxy solicitation?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay for the entire cost of soliciting proxies. In addition to these mailed proxy materials, our directors, officers and
employees may also solicit proxies in person, by telephone, or by other means of communication. Directors, officers and employees will not be paid any additional compensation for soliciting proxies. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


What does it mean if I receive more than one proxy card?  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you receive more than one proxy card, your shares are registered in more than one name or are registered in different accounts.
Please complete, sign and return each proxy card to ensure that all of your shares are voted. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Can I change my vote after submitting my proxy?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the stockholder of record of your
shares, you may revoke your proxy in any one of three ways:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> You may submit another properly completed proxy with a later date. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> You may send a timely written notice that you are revoking your proxy to the Company's Corporate Secretary at Mirna
Therapeutics,&nbsp;Inc., 2150 Woodward Street, Austin, Texas 78744. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> You may attend the Annual Meeting and vote in person. Simply attending the Annual Meeting will not, by itself, revoke your proxy. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held by your broker or other agent, you should follow the instructions provided by your broker or agent. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


What is the quorum requirement?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of
the outstanding shares entitled to vote are present at the Annual Meeting. On April&nbsp;20, 2016, there were 20,830,555 shares outstanding and entitled to vote. Accordingly, we expect that the
holders of at least 10,415,278 shares must be present at the Annual Meeting to have a quorum. Your shares will be counted toward the quorum at the Annual Meeting only if you vote in person at the
meeting, or you submit a valid proxy vote. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abstentions
and broker non-votes (as described below) will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present and entitled to
vote at the meeting in person or represented by proxy may adjourn the Annual Meeting to another date. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


How are votes counted?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes will be counted by the Inspector of Elections appointed for the Annual Meeting. The Inspector of Elections will separately count
"</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>," "</FONT><FONT SIZE=2><B>WITHHOLD</B></FONT><FONT SIZE=2>" and broker non-votes for Proposal No.&nbsp;1 (the election of directors) and
"</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" and "</FONT><FONT SIZE=2><B>AGAINST</B></FONT><FONT SIZE=2>" votes, abstentions and, if any, broker non-votes for Proposal No.&nbsp;2 (the
ratification of the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as the independent registered accounting firm of the Company for the fiscal year ending December&nbsp;31, 2016). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held by your broker or other agent as your nominee (that is, held beneficially in "street name"), you will need to obtain a proxy form from the institution that holds
your shares and follow the instructions included on that form regarding how to instruct your broker or other agent to vote your shares. If you do not give voting instructions to your broker or other
agent, your broker or other agent can only vote your shares with respect to "routine" matters (as described below). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=182034,FOLIO='4',FILE='DISK122:[16ZBA1.16ZBA49201]DA49201A.;9',USER='DNICHOL',CD='26-APR-2016;16:39' -->
<A NAME="page_da49201_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


What are "broker non-votes"?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you hold shares beneficially in street name and do not provide your broker with voting instructions, your shares may constitute
"broker non-votes." Broker non-votes occur on a matter when a broker is not permitted to vote on that matter without instructions from the beneficial owner and instructions are not given. These
matters are referred to as "non-routine" matters. Proposal No.&nbsp;1, to elect directors, is a non-routine matter, but Proposal No.&nbsp;2, to ratify the selection of our independent registered
public accounting firm, is a "routine" matter. Broker non-votes will not be counted toward the vote total for any proposal at the Annual Meeting. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


How many votes are needed to approve each proposal?  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Proposal No.&nbsp;1&#151;To elect three Class&nbsp;I directors to hold office until the 2019 Annual Meeting of Stockholders
or until their successors are elected. The two nominees receiving the most "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" votes (from the votes of shares present in person or represented by
proxy and entitled to vote on the election of directors) will be elected. Broker non-votes will not be counted towards the vote total for this proposal. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Proposal No.&nbsp;2&#151;To ratify the selection, by the audit committee of our board of directors, of Ernst&nbsp;&amp;
Young&nbsp;LLP as the independent registered public accounting firm of the Company for the fiscal year ending December&nbsp;31, 2016. "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" votes
from the holders of a majority of the shares cast (excluding abstentions and broker non-votes) are required to approve this proposal. Because Proposal No.&nbsp;2 is considered a "routine" matter,
broker non-votes are not expected in connection with this proposal. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


How can I find out the results of the voting at the Annual Meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will disclose final voting results in a Current Report on Form&nbsp;8-K filed with the SEC within four business days after the
Annual Meeting. If final voting results are unavailable at that time, then we intend to file&nbsp;a Current Report on Form&nbsp;8-K to disclose preliminary voting results and file an amended
Current Report on Form&nbsp;8-K within four business days after the date the final voting results are available. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


When are stockholder proposals due for next year's annual meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be considered for inclusion in the proxy materials for the 2017 Annual Meeting of Stockholders, your proposal must be submitted in
writing by December&nbsp;27, 2016 to the Company's Corporate Secretary at Mirna Therapeutics,&nbsp;Inc., 2150 Woodward Street, Suite&nbsp;100, Austin, Texas 78744. However, if the meeting is
more than 30&nbsp;days from June&nbsp;29, 2017, then the deadline will be a reasonable time before we begin to print and mail our proxy materials for that meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you wish to submit a proposal before the stockholders or nominate a director at the 2017 Annual Meeting of Stockholders, but you are not requesting that your proposal or nomination be
included in the proxy materials for that meeting, then you must follow the procedures set forth in our bylaws and, among other things, notify the Company's Corporate Secretary in writing between
March&nbsp;1, 2017 and March&nbsp;31, 2017. However, if the date of the 2017 Annual Meeting of Stockholders is more than 30&nbsp;days before or more than 60&nbsp;days after June&nbsp;29,
2017, then you must give notice not later than the 90<SUP>th</SUP>&nbsp;day prior to that meeting or, if later, the 10<SUP>th</SUP>&nbsp;day following the day on which public disclosure of
that annual meeting date is first made. You are also advised to review our bylaws, which contain additional requirements regarding advance notice of stockholder proposals and director nominations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=380770,FOLIO='5',FILE='DISK122:[16ZBA1.16ZBA49201]DA49201A.;9',USER='DNICHOL',CD='26-APR-2016;16:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc49201_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc49201_proposal_no._1_election_of_directors"> </A>
<A NAME="toc_dc49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1<BR>  ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors is divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of
directors, and each class has a three-year term. Except as otherwise provided by law, vacancies on the board of directors may be filled only by individuals elected by a majority of the remaining
directors. A director elected by the board of directors to fill a vacancy in a particular class, including a vacancy created by an increase in the number of directors, shall serve for the remainder of
the full term of that class and until such director's successor is elected and qualified, or until such director's earlier death, resignation or removal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors currently consists of eight directors and no vacancies, divided into the three following classes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Class&nbsp;I directors are Elaine V. Jones, Ph.D., Matthew Winkler, Ph.D. and Peter S. Greenleaf, whose current terms will
expire at the Annual Meeting; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Class&nbsp;II directors are Lawrence M. Alleva and Michael Powell, Ph.D., whose current terms will expire at the 2017 Annual
Meeting of Stockholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Class&nbsp;III directors are Paul Lammers, M.D., M.Sc., Edward Mathers and Clay B. Siegall, Ph.D., whose current terms will
expire at the 2018 Annual Meeting of Stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Winkler,
Mr.&nbsp;Greenleaf and Dr.&nbsp;Perry Nisen, M.D., Ph.D. have been nominated to serve as Class&nbsp;I directors and have agreed to stand for election. If the
nominees for Class&nbsp;I are elected at the Annual Meeting, then each nominee will serve for a three-year term expiring at the 2019 Annual Meeting of Stockholders, or until his or her successor is
elected and qualified, or until his or her earlier death, resignation or removal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
directors are elected by a plurality of the votes cast. If a choice is specified on the proxy card by a stockholder, the shares will be voted as specified. If a choice is not
specified on the proxy card, and authority to do so is not withheld, the shares will be voted "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the election of the three nominees for
Class&nbsp;I above. If any of the nominees becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for the nominee will instead be voted for the
election of a substitute nominee proposed by the Company's management or the board of directors. Each person nominated for election has agreed to serve if elected. Our management has no reason to
believe that any nominee will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following is a brief biography and discussion of the specific attributes, qualifications, experience and skills of each nominee for director and each director whose term will
continue after the Annual Meeting. Our board of directors and management encourage each nominee for director and each continuing director to attend the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>
"FOR" EACH OF THE THREE CLASS I NOMINEES FOR DIRECTOR.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=139797,FOLIO='6',FILE='DISK122:[16ZBA1.16ZBA49201]DC49201A.;6',USER='BKYNARD',CD='26-APR-2016;12:50' -->
<A NAME="page_dc49201_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth, for the Class&nbsp;I nominees and for our other current directors who will continue in office after the Annual Meeting,
information with respect to their ages and position held within the Company. Dr.&nbsp;Winkler is standing for re-election and Dr.&nbsp;Nisen and Mr.&nbsp;Greenleaf are standing for their initial
election by our stockholders. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="210pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position/Office Held With the Company </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Director<BR>
Since </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=8 VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I> Class&nbsp;I Directors whose terms expire at the Annual Meeting</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matthew Winkler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2007</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter S. Greenleaf</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Perry Nisen, M.D., Ph.D.(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=8 VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I> Class&nbsp;II Directors whose terms expire at the 2017 Annual Meeting of Stockholders</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva(1)(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Powell, Ph.D.(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=8 VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I> Class&nbsp;III Directors whose terms expire at the 2018 Annual Meeting of Stockholders</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul Lammers, M.D., M.Sc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2009</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward Mathers(2)(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clay B. Siegall, Ph.D.(1)(2)(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the audit committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the compensation committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the nominating and corporate governance committee.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Nominees for Election to a Three-Year Term Expiring at the 2019 Annual Meeting of Stockholders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Perry Nisen, M.D., Ph.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Nisen is standing for election at our Annual Meeting. He has been Chief Executive Officer of Sanford
Burnham
Prebys Medical Discovery Institute, a non-profit medical research institute, since August 2014 and holds the Donald Bren Chief Executive Chair. From June 2004 to September 2014, Dr.&nbsp;Nisen
served in various roles at GlaxoSmithKline, including most recently
Senior Vice President of Science and Innovation, as well as Chief Medical Officer, Senior Vice President and Oncology Therapy Area Head, Senior Vice President of Cancer Research, Senior Vice President
of Clinical Pharmacology and Discovery Medicine. Before that, Dr.&nbsp;Nisen was Divisional Vice President of Cancer Research and Oncology Development at Abbott Laboratories. Dr.&nbsp;Nisen holds
a B.S. from Stanford University and M.D. and Ph.D. degrees from the Albert Einstein College of Medicine. Dr.&nbsp;Nisen has been chosen to join our Board because of his medical and scientific
expertise, experience in the healthcare industry and broad management experience. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Matthew Winkler, Ph.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Matthew Winkler was our founder and has served as a member of our board of directors since December 2007,
 including
as Chairman until October 2012. During 2008 to 2009, Dr.&nbsp;Winkler served as our Executive Chairman. Since January 2013, Dr.&nbsp;Winkler has been the Chairman of the board of directors of
Asuragen,&nbsp;Inc. ("Asuragen"), a molecular diagnostic and pharmacogenomics service company, where he also served as the Chief Executive Officer from 2006 to December 2012. Prior to Asuragen,
Dr.&nbsp;Winkler was the founder and Chief Executive Officer of Ambion,&nbsp;Inc., a privately held company that developed and sold research reagents for RNA analysis. Until March 2016,
Dr.&nbsp;Winkler served on the board of Second Genome, a biotherapeutics company. Dr.&nbsp;Winkler received a B.S. in Genetics and a Ph.D. in Zoology from the University of California at Berkeley.
Dr.&nbsp;Winkler was an Assistant and Associate Professor of Zoology at the University of Texas from 1983 to 1991. Dr.&nbsp;Winkler has been chosen to serve on our board of directors due to his
management experience in the life sciences and pharmaceutical industries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peter S. Greenleaf.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Greenleaf has been the Chief Executive Officer and a Director of Sucampo Pharmaceuticals,&nbsp;Inc. since
March 2014
and was appointed chairman of the board in January </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=751641,FOLIO='7',FILE='DISK122:[16ZBA1.16ZBA49201]DC49201A.;6',USER='BKYNARD',CD='26-APR-2016;12:50' -->
<A NAME="page_dc49201_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>2016.
In addition, Mr.&nbsp;Greenleaf is currently a Director of Mast Therapeutics,&nbsp;Inc. and has served since November 2015. Prior to his leadership of Sucampo, Mr.&nbsp;Greenleaf was CEO
and a board member of Histogenics Corporation, a regenerative medicine company, from June 2013 through February 2014. From April 2006 to June 2013, Mr.&nbsp;Greenleaf was employed by
MedImmune&nbsp;LLC, the global biologics arm of AstraZeneca, where he most recently served as President. While at MedImmune, Mr.&nbsp;Greenleaf was instrumental in driving the expansion of
MedImmune's pipeline into over 120 clinical and pre-clinical programs and the commercialization of its marketed products. Mr.&nbsp;Greenleaf also served as President of MedImmune Ventures from
January 2010 to June 2013, a wholly owned venture capital fund within the AstraZeneca Group, where he led investment in emerging biopharmaceutical, medical device, and diagnostic companies. Prior to
serving as President of MedImmune, Mr.&nbsp;Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions.
Mr.&nbsp;Greenleaf has also held senior commercial roles at Centocor Biotech,&nbsp;Inc. (now Jansen Biotechnology, Johnson&nbsp;&amp; Johnson) from 1998 to 2006 and prior to that Boehringer Mannheim
G.m.b.H. (now Roche Holdings) from 1996 to 1998. Mr.&nbsp;Greenleaf currently chairs the Maryland
Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr.&nbsp;Greenleaf is also a member
of the board of directors of the Biotechnology Industry Organization (BIO), where he also serves on the Governing Board of the Emerging Companies Section. He is also a member of the board of directors
of the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr.&nbsp;Greenleaf's previous Board appointments include the University of Maryland Baltimore Foundation,&nbsp;Inc.; Rib-X
Pharmaceuticals; LigoCyte Pharmaceuticals; and Corridor Pharmaceuticals. He received a Master of Business Administration degree from St.&nbsp;Joseph's University and a Bachelor of Science degree
from Western Connecticut State University. Mr.&nbsp;Greenleaf has been chosen to serve on our board of directors due to his leadership experience and extensive commercialization, strategic planning,
and drug development experience in the biopharmaceutical industry. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>
FOR THE ELECTION OF EACH OF THE ABOVE NAMED NOMINEES  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Directors Continuing in Office Until the 2017 Annual Meeting of Stockholders  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lawrence M. Alleva.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Lawrence M. Alleva joined our board in July 2014. Prior to his retirement in June 2010, Mr.&nbsp;Alleva
worked with
PricewaterhouseCoopers&nbsp;LLP, or PwC, for 39&nbsp;years, 28 of which as a partner with the firm. Mr.&nbsp;Alleva served clients primarily in the technology sector, including numerous
pharmaceutical and biotechnology companies. Additionally, he served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader
(Assurance) for PwC from 2006 until his retirement. Mr.&nbsp;Alleva is a Certified Public Accountant (inactive). Mr.&nbsp;Alleva received a Bachelor of Science degree from Ithaca College (magna
cum laude) and attended Columbia University's Executive MBA program. Mr.&nbsp;Alleva also serves as a director for public companies Tesaro&nbsp;Inc. and Bright Horizons Family Solutions, and
previously served on the board of GlobalLogic&nbsp;Inc. Mr.&nbsp;Alleva has been chosen to serve on our board of directors due to his financial and accounting experience as a director and a public
accounting partner serving multiple healthcare, pharmaceutical and biopharmaceutical companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael Powell, Ph.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Michael Powell has served as Chairman of our board of directors since October 2012. Since 1997,
Dr.&nbsp;Powell
has been a General Partner of Sofinnova Ventures, a venture capital firm. Previously, Dr.&nbsp;Powell has held positions at Genentech, a biotechnology company, Cytel, a research and development
company, and Syntex Research Group, a pharmaceutical company. Dr.&nbsp;Powell is currently a director of Dauntless Pharmaceuticals, a biopharmaceutical company, Alvine
Pharmaceuticals, a biopharmaceutical company, Ascenta Therapeutics, a biopharmaceutical company, Checkmate Pharmaceuticals, a biopharmaceutical company, Dauntless 1, a biopharmaceutical company, and
Ocera Therapeutics, a publicly traded biopharmaceutical company. Dr.&nbsp;Powell is an Adjunct </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=262197,FOLIO='8',FILE='DISK122:[16ZBA1.16ZBA49201]DC49201A.;6',USER='BKYNARD',CD='26-APR-2016;12:50' -->
<A NAME="page_dc49201_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Professor
at the University of Kansas. Dr.&nbsp;Powell is the Board President of the AIDS Vaccine Advocacy Coalition and serves on the advisory board of the Institute for the Advancement of Medical
Innovation at the University of Kansas. Dr.&nbsp;Powell received a B.S. in Chemistry from Scarborough College, a Ph.D. in Physical Chemistry from the University of Toronto and completed his
post-doctorate work in Bioorganic Chemistry at the University of California. Dr.&nbsp;Powell has been chosen to serve on our board of directors due to his experience with the life sciences and
pharmaceutical industries and the venture capital industry. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Directors Continuing in Office Until the 2018 Annual Meeting of Stockholders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paul Lammers, M.D., M.Sc.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Paul Lammers has served as a member of our board of directors and as our President and Chief
Executive Officer
since November 2009. Previously, Dr.&nbsp;Lammers was the President of Repros Therapeutics&nbsp;Inc., or Repros Therapeutics, a biopharmaceutical company, from February 2009 until October 2009.
From August 2002 until September 2008, Dr.&nbsp;Lammers served as the Chief Medical Officer for EMD Serono,&nbsp;Inc., a biopharmaceutical division of Merck KGaA, a global pharmaceutical and
chemical group. Previously, Dr.&nbsp;Lammers served as the Senior Vice President of clinical and regulatory affairs at Zonagen,&nbsp;Inc., which later became Repros Therapeutics.
Dr.&nbsp;Lammers began his career with Organon International, a pharmaceutical company, spending eight years in the commercial and clinical operations in Europe and the United States.
Dr.&nbsp;Lammers received a M.Sc. and M.D. from the Catholic University (Radboud University) in Nijmegen, The Netherlands. Dr.&nbsp;Lammers has been chosen to serve on our board of directors due
to his management experience in multiple pharmaceutical and biopharmaceutical companies and drug development. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Edward Mathers.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Edward Mathers has served as a member of our board of directors since October 2012. Since August 2008,
Mr.&nbsp;Mathers
has been a Partner at New Enterprise Associates,&nbsp;Inc., or NEA, a private venture capital firm focusing on technology and healthcare investments. Mr.&nbsp;Mathers serves on
the board of directors of the following pharmaceutical companies: Amplyx Pharmaceuticals,&nbsp;Inc., ObsEva&nbsp;SA, SunLogic,&nbsp;LLC, Ziarco Group Limited, Envisia Therapeutics,&nbsp;Inc.,
Ra Pharmaceuticals,&nbsp;Inc., Rhythm Pharmaceuticals, and Lumos Pharma. Mr.&nbsp;Mathers also serves on the board of directors of Liquidia Technologies, a biotechnology company. From 2002 to
2008, Mr.&nbsp;Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune,&nbsp;Inc. ("MedImmune"), and led its venture capital subsidiary, MedImmune
Ventures,&nbsp;Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Previously, Mr.&nbsp;Mathers spent
15&nbsp;years at Glaxo Wellcome,&nbsp;Inc. where he held various sales and marketing positions. Mr.&nbsp;Mathers received a B.S. in Chemistry from North Carolina State University.
Mr.&nbsp;Mathers has been chosen to serve on our board of directors due to his experience with the healthcare and pharmaceutical industries and his broad management experience. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clay B. Siegall, Ph.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Clay B. Siegall has served a member of our board of directors since January 2013. Dr.&nbsp;Siegall
founded
Seattle Genetics,&nbsp;Inc. ("Seattle Genetics"), a biotechnology company, in 1997, where he has served as the Chief Executive Officer since November 2002, as the President since June 2000 and as
the Chairman of the board of directors since March 2004. Dr.&nbsp;Siegall also served as the Chief Scientific Officer of Seattle Genetics from December 1997 until November 2002. Dr.&nbsp;Siegall
currently serves on the board of directors of Alder BioPharmaceuticals,&nbsp;Inc., a biopharmaceutical company, and Ultragenyx Pharmaceutical, a pharmaceutical company. Prior to co-founding Seattle
Genetics, Dr.&nbsp;Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997, most recently as a Principal Scientist. From 1988 to 1991, Dr.&nbsp;Siegall was a
Staff Fellow/Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. Dr.&nbsp;Siegall received a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics
from George Washington University. Dr.&nbsp;Siegall has been chosen to serve on our board of directors due to his experience as a director and executive of multiple healthcare and biopharmaceutical
companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=868433,FOLIO='9',FILE='DISK122:[16ZBA1.16ZBA49201]DC49201A.;6',USER='BKYNARD',CD='26-APR-2016;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de49201_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49201_proposal_no._2_ratification_of__pro03498"> </A>
<A NAME="toc_de49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2<BR>  RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The audit committee of our board of directors has selected Ernst&nbsp;&amp; Young&nbsp;LLP, or EY, as our independent registered public
accounting firm for the year ending December&nbsp;31, 2016, and is seeking ratification of such selection by our stockholders at the Annual Meeting. EY has audited our financial statements for the
fiscal years ended December&nbsp;31, 2015 and 2014. Representatives of EY are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and
will be available to respond to appropriate questions </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
our bylaws nor other governing documents or law require stockholder ratification of the selection of EY as our independent registered public accounting firm. However, the audit
committee is submitting the selection of EY to our stockholders for ratification as a matter of good corporate
practice. If our stockholders fail to ratify the selection, the audit committee will reconsider whether or not to retain EY. Even if the selection is ratified, the audit committee in its discretion
may select a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of the Company and our
stockholders. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Principal Accountant Fees and Services  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the fiscal years ended December&nbsp;31, 2015 and 2014, EY billed the approximate fees set forth below. All fees included below
were approved by the audit committee. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>634,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>550,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total All Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>634,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>550,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of fees billed for professional services rendered for the audit of our annual financial statements, quarterly interim reviews, and services
provided in connection with our securities offerings and registration statements.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Pre-Approval Policies and Procedures  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The audit committee has adopted a policy for the pre-approval of all audit and non-audit services to be performed for the Company by
the independent registered public accounting firm. This policy is set forth in the charter of the audit committee and available at http://investor.mirnarx.com/corporate-governance.cfm. The audit
committee approved all of the audit, audit-related, tax and other services provided by EY since our initial public offering in September 2015 and the estimated costs of those services. Actual amounts
billed, to the extent in excess of the estimated amounts, are periodically reviewed and approved by the audit committee. The audit committee has considered the role of EY in providing audit and
audit-related services to the Company and has concluded that such services are compatible with EY's role as the Company's independent registered public accounting firm. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE </B></FONT><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2><B> RATIFICATION OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=478588,FOLIO='10',FILE='DISK122:[16ZBA1.16ZBA49201]DE49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg49201_1_11"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49201_report_of_the_audit_co__dg402260"> </A>
<A NAME="toc_dg49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The material in this report is not "soliciting material," is not deemed "filed" with the SEC, and is not to be
incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary purpose of the audit committee is to oversee our financial reporting processes on behalf of our board of directors. The audit committee's functions are more fully described
in its charter, which is available on our website at http://investor.mirnarx.com/corporate-governance.cfm. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
fulfilling its oversight responsibilities, the audit committee reviewed and discussed with management the Company's audited financial statements for the fiscal year ended
December&nbsp;31, 2015. The audit committee has discussed with EY, the Company's independent registered public accounting firm, the matters required to be discussed by Auditing Standard
No.&nbsp;16, "Communications with Audit Committees," issued by the Public Company Accounting Oversight Board, or PCAOB. In addition, the audit committee has discussed with EY their independence, and
received from EY the written disclosures and the letter required by Ethics and Independence Rule&nbsp;3526 of the PCAOB. Finally, the audit committee discussed with EY, with and without management
present, the scope and results of EY's audit of the financial statements for the fiscal year ended December&nbsp;31, 2015. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on these reviews and discussions, the audit committee has recommended to our board of directors that such audited financial statements be included in our Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2015 for filing with the SEC. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> Audit Committee</B></FONT><FONT SIZE=2><BR>
Lawrence M. Alleva, Chairman<BR>
Elaine V. Jones<BR>
Clay B. Siegall, Ph.D.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=228540,FOLIO='11',FILE='DISK122:[16ZBA1.16ZBA49201]DG49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di49201_1_12"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di49201_corporate_governance"> </A>
<A NAME="toc_di49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Composition  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Director Independence  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors currently consists of eight members. Our board of directors has determined that all of our directors, other than
Dr.&nbsp;Paul Lammers, qualify as "independent" directors in accordance with the NASDAQ listing requirements. Dr.&nbsp;Lammers is not considered independent because he is an employee of Mirna. The
NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director nor
any of his family members has engaged in various types of business dealings with us. In addition, as required by NASDAQ rules, our board of directors has made a subjective determination as to each
independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a
director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and
relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive officers. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Classified Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with our amended and restated certificate of incorporation, our board of directors is divided into three classes with
staggered, three-year terms as set forth below. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and
qualification until the third annual meeting following election. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Class&nbsp;I directors are Dr.&nbsp;Jones, Dr.&nbsp;Winkler and Mr.&nbsp;Greenleaf, and their terms will expire at the
Annual Meeting; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Class&nbsp;II directors are Mr.&nbsp;Alleva and Dr.&nbsp;Powell, and their terms will expire at the 2017 Annual Meeting of
Stockholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Class&nbsp;III directors are Dr.&nbsp;Lammers, Mr.&nbsp;Mathers and Dr.&nbsp;Siegall, and their terms will expire at 2018
Annual Meeting of Stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be
distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of our board of directors into three classes with staggered
three-year terms may delay or prevent a change of our management or a change in control of our company. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Leadership Structure of the Board  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has separated the positions of Chairman of the board and Chief Executive Officer. Separating these positions
allows our Chief Executive Officer to focus on our day-to-day business, while allowing the Chairman of the board to lead the board in its fundamental role of providing advice to and independent
oversight of management. The board recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position in the current business environment, as well as the
commitment required to serve as Chairman of the board, particularly as the board's oversight responsibilities continue to grow. While our bylaws and corporate governance guidelines do not require that
our Chairman and Chief Executive Officer positions be separate, the board believes that having separate positions and having an independent outside director serve as Chairman is the appropriate
leadership structure for us and demonstrates our commitment to good </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=61199,FOLIO='12',FILE='DISK122:[16ZBA1.16ZBA49201]DI49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_di49201_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>corporate
governance. However, our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Role of Board in Risk Oversight Process  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors encourages
management to promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular
management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior
management reviews these risks with the board of directors at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and
presents the steps taken by management to mitigate or eliminate such risks. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as
through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring
and assessing strategic risk exposure, our audit committee is responsible for overseeing our major financial risk exposures and the steps our management has taken to monitor and control these
exposures. The audit committee also monitors compliance with legal and regulatory requirements. Our nominating and governance committee monitors the effectiveness of our corporate governance
guidelines and considers and approves or disapproves any related-persons transactions. Our compensation committee assesses and monitors whether any of our compensation policies and programs has the
potential to encourage excessive risk-taking. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Meetings of the Board of Directors and Committees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2015, the board of directors met thirteen times, the audit committee met six times, and the compensation committee met one time.
The nominating and corporate governance committee did not meet during 2015. In that year, each incumbent director attended at least 75% of the meetings of the board of directors and the committees on
which he served. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Committees  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our audit committee oversees our corporate accounting and financial reporting process. Among other matters, the audit
committee:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appoints our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluates the independent registered public accounting firm's qualifications, independence and performance; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> determines the engagement of the independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviews and approves the scope of the annual audit and the audit fee; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discusses with management and the independent registered public accounting firm the results of the annual audit and the review of our
quarterly financial statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approves the retention of the independent registered public accounting firm to perform any proposed permissible non-audit services; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=417377,FOLIO='13',FILE='DISK122:[16ZBA1.16ZBA49201]DI49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_di49201_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitors the rotation of partners of the independent registered public accounting firm on our engagement team as required by law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> is responsible for reviewing our financial statements and our management's discussion and analysis of financial condition and results
of operations to be included in our annual and quarterly reports to be filed with the SEC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviews our critical accounting policies and estimates; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> annually reviews the audit committee charter and the committee's performance. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
current members of our audit committee are Mr.&nbsp;Alleva, who serves as the chairman of the committee, Dr.&nbsp;Jones and Dr.&nbsp;Siegall. After the Annual Meeting, assuming
the election of the three
Class&nbsp;I nominees set forth herein, our audit committee will be composed of Mr.&nbsp;Alleva, as chairman, Mr.&nbsp;Greenleaf and Dr.&nbsp;Nisen. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
the election of the three Class&nbsp;I nominees set forth herein, each of the expected members of our audit committee will meet the requirements for financial literacy under
the applicable rules and regulations of the SEC and NASDAQ. Our board of directors has determined that Mr.&nbsp;Alleva is an audit committee financial expert as defined under the applicable rules of
the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of NASDAQ. Under the rules of the SEC, members of the audit committee must also meet
heightened independence standards. Our board of directors has determined that, assuming the election of the three Class&nbsp;I nominees set forth herein, each the expected members of our audit
committee will be independent under the heightened independence standards under the applicable rules of NASDAQ. The audit committee operates under a written charter that satisfies the applicable
standards of the SEC and NASDAQ. A copy of the audit committee charter is available to security holders on the Company's website at http://investor.mirnarx.com/corporate-governance.cfm. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee reviews and recommends policies relating to compensation and benefits of our officers and employees. The
compensation committee reviews and recommends corporate goals and objectives relevant to compensation of our Chief Executive Officer and other executive officers, evaluates the performance of these
officers in light of those goals and objectives and recommends to our board of directors the compensation of these officers based on such evaluations. The compensation committee also recommends to our
board of directors the issuance of stock options and other awards under our stock plans. The compensation committee will review and evaluate, at least annually, the performance of the compensation
committee and its members, including compliance by the compensation committee with its charter. The current members of our compensation committee are Dr.&nbsp;Powell, who serves as the chairperson
of the committee, Dr.&nbsp;Siegall and Mr.&nbsp;Mathers. Each of the members of our compensation committee is independent under the applicable rules and regulations of NASDAQ, is a "non-employee
director" as defined in Rule&nbsp;16b-3 promulgated under the Exchange Act and is an "outside director" as that term is defined in Section&nbsp;162(m) of the U.S. Internal Revenue Code of 1986, as
amended, or Section&nbsp;162(m). The compensation committee operates under a written charter that satisfies the applicable standards of the SEC and NASDAQ. A copy of the compensation committee
charter is available to security holders on the Company's website at http://investor.mirnarx.com/corporate-governance.cfm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation committee has retained Radford,&nbsp;Inc. ("Radford") a nationally recognized compensation consulting firm, to serve as its independent compensation consultant and to
conduct market research and analysis on our various executive positions, to assist the committee in developing appropriate incentive plans for our executives on an annual basis, to provide the
committee with advice and ongoing recommendations regarding material executive compensation decisions, and to review </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=422080,FOLIO='14',FILE='DISK122:[16ZBA1.16ZBA49201]DI49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_di49201_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>compensation
proposals of management. Radford reports directly to the compensation committee and does not provide any non-compensation related services to us. In compliance with the disclosure
requirements of the SEC regarding the independence of compensation consultants, Radford addressed each of the six independence factors established by the SEC with our compensation committee. Its
responses affirmed the independence of Radford on executive compensation matters. Based on this assessment, our compensation committee determined that the engagement of Radford does not raise any
conflicts of interest or similar concerns. In addition, our compensation committee evaluated the independence of its other outside advisors to the compensation committee, including outside legal
counsel, considering the same independence factors and concluded their work for our compensation committee does not raise any conflicts of interest. Our compensation committee operates under a written
charter that satisfies the applicable standards of the SEC and NASDAQ. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nominating and corporate governance committee is responsible for making recommendations to our board of directors regarding
candidates for directorships and the size and composition of our board of directors. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate
governance policies and reporting and making recommendations to our board of directors concerning governance matters. The current members of our nominating and corporate governance committee are
Mr.&nbsp;Mathers, who serves as the chairman of the committee, Dr.&nbsp;Siegall and Mr.&nbsp;Alleva. Mr.&nbsp;Mathers serves as the chairman of the committee. Each of the members of our
nominating and corporate governance committee is an independent director under the applicable rules and regulations of NASDAQ relating to nominating and corporate governance committee independence.
The nominating and corporate governance committee operates under a written charter. A copy of the nominating and corporate governance committee charter is available to security holders on the
Company's website at http://investor.mirnarx.com/corporate-governance.cfm. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Diversity  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee is responsible for reviewing with the board of directors, on an annual basis, the
appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new
candidates and current members), the nominating and
corporate governance committee, in recommending candidates for election (and, in the case of vacancies, appointing), and the board of directors, in approving such candidates, will take into account
many factors, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> personal and professional integrity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ethics and values; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> experience in corporate management, such as serving as an officer or former officer of a publicly held company; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> experience in the industries in which we compete; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> experience as a board member or executive officer of another publicly held company; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> conflicts of interest; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> practical and mature business judgment. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=284032,FOLIO='15',FILE='DISK122:[16ZBA1.16ZBA49201]DI49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_di49201_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently,
our board of directors evaluates each individual in the context of the board of directors as a whole, with the objective of assembling a group that can best maximize the
success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including those
officers responsible for financial reporting. The code of business conduct and ethics is available on our website at http://investor.mirnarx.com/corporate-governance.cfm. We will disclose any
substantive amendments to the code of business conduct and ethics, or any waiver of its provisions, on our website. The reference to our website does not constitute incorporation by reference of the
information contained at or available through our website. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Limitation on Liability and Indemnification Matters  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary
damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as
directors, except liability for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any breach of the director's duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General
Corporation Law; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any transaction from which the director derived an improper personal benefit. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation and amended and restated bylaws provide that we are required to indemnify our directors and officers, in each case to the fullest
extent permitted by Delaware law. Our amended and restated bylaws also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any
action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of
whether we would otherwise be permitted to indemnify him or her under Delaware law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified
exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys' fees, judgments, fines and settlement amounts incurred by any of these
individuals in any action or proceeding brought against them by reason of the fact that they are or were our agents. We believe that these provisions in our amended and restated certificate of
incorporation and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified directors and officers. We also maintain directors' and officers' liability
insurance. This description of the limitation of liability and indemnification provisions of our amended and restated certificate of incorporation, of our amended and restated bylaws and of our
indemnification agreements is qualified in its entirety by reference to these documents. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from
bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though
an action, if successful, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=19,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=793577,FOLIO='16',FILE='DISK122:[16ZBA1.16ZBA49201]DI49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_di49201_1_17"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>might
benefit us and our stockholders. Further, a stockholder's investment may be adversely affected to the extent that we pay the costs of settlement and damage. To the extent the indemnification for
liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the
opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. At present, there is no pending litigation or proceeding
involving any of our directors, officers or employees for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims for indemnification. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Director Attendance at Annual Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has a policy of encouraging director attendance at our annual meetings of stockholders, but attendance is not
mandatory. Our board of directors and management team encourage all of our directors to attend the Annual Meeting. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stockholder Communications with the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stockholder may communicate with the board of directors, or an individual director, by sending written correspondence to the
Company's Corporate Secretary at Mirna Therapeutics,&nbsp;Inc., 2150 Woodward Street, Suite&nbsp;100, Austin, Texas 78744. The Corporate Secretary will review such correspondence and forward it to
the board of directors, or an individual director, as appropriate. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2015, Dr.&nbsp;Powell, Mr.&nbsp;Mathers, and Dr.&nbsp;Siegall served as members of our compensation committee. During
2015, none of the members of our compensation committee has at any time been one of our officers or employees. None of our executive officers currently serves, or in the past year has served, as a
member of the board of directors or compensation committee of any entity that has one or more executive officers on our board of directors or compensation committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=20,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=340743,FOLIO='17',FILE='DISK122:[16ZBA1.16ZBA49201]DI49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk49201_1_18"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk49201_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_dk49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of transactions since January&nbsp;1, 2015 to which we have been a party, in which the amount involved
exceeds $120,000, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct
or indirect material interest. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Indemnification Agreements and Directors' and Officers' Liability Insurance  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other
things, require us to indemnify each director and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys' fees, judgments, penalties
fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person's services as
a director or executive officer. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Investor Rights Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into an amended and restated investor rights agreement with certain holders of our common stock. As of
December&nbsp;31, 2015, the holders of approximately 13.9&nbsp;million shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Policies and Procedures for Related Party Transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has adopted a written related person transaction policy setting forth the policies and procedures for the review
and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item&nbsp;404 of Regulation&nbsp;S-K under the Securities Act, any
transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000
and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the
related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is
tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm's length transaction
with an unrelated third party and the extent of the related person's interest in the transaction. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=21,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=744424,FOLIO='18',FILE='DISK122:[16ZBA1.16ZBA49201]DK49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm49201_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm49201_non-employee_director_compensation"> </A>
<A NAME="toc_dm49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  NON-EMPLOYEE DIRECTOR COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we did not maintain a formal director compensation policy from January&nbsp;1, 2015 until our initial public offering in
October 2015, during this period, our independent directors, who we considered to be those non-employee directors not associated with a principal investor in our company, including Drs. Goodman and
Siegall and Mr.&nbsp;Alleva, received an annual cash retainer of $25,000 for service as a director, pro-rated for partial years of service, and an additional cash retainer of $3,000 per meeting of
the board or a committee of the board attended in person and $2,000 per meeting of the board or committee of the board attended telephonically. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with our initial public offering in October 2015, we approved a compensation policy for our non-employee directors, or the Director Compensation Program. Pursuant to the
Director
Compensation Program, our non-employee directors are entitled to receive cash compensation, paid quarterly in arrears, as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Each non-employee director receives an annual cash retainer in the amount of $35,000 per year. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Any non-employee Chairman receives an additional annual cash retainer in the amount of $25,000 per year. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The chairperson of the audit committee receives additional annual cash compensation in the amount of $15,000 per year for such
chairperson's service on the audit committee. Each non-chairperson member of the audit committee receives additional annual cash compensation in the amount of $7,500 per year for such member's service
on the audit committee. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The chairperson of the compensation committee receives additional annual cash compensation in the amount of $10,000 per year for such
chairperson's service on the compensation committee. Each non-chairperson member of the compensation committee receives additional annual cash compensation in the amount of $5,000 per year for such
member's service on the compensation committee. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The chairperson of the nominating and corporate governance committee receives additional annual cash compensation in the amount of
$7,500 per year for such chairperson's service on the nominating and corporate governance committee. Each non-chairperson member of the nominating and corporate governance committee receives
additional annual cash compensation in the amount of $3,750 per year for such member's service on the nominating and corporate governance committee. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Director Compensation Program, upon a director's initial appointment or election to our board of directors, such non-employee director will receive an option (the Initial
Grant) to purchase 12,000 shares of our common stock (subject to adjustment as provided in the applicable equity plan). In
addition, each non-employee director who has been serving as a director for at least three months prior to any annual stockholder meeting following the date of this offering and will continue to serve
as a director immediately following such annual stockholder meeting will be automatically granted, on the date of such annual stockholder meeting, an option (the Annual Grant) to purchase 6,000 shares
of our common stock (subject to adjustment as provided in the applicable equity plan). The Initial Grant will vest in substantially equal installments on each of the first three anniversaries of the
applicable grant date, subject to continued service through each applicable vesting date, and the Annual Grant will vest in full on the earlier of the first anniversary of the applicable grant date or
immediately prior to the next annual stockholder meeting after the applicable grant date, subject to continued service through such vesting date. In addition, pursuant to the terms of the Director
Compensation Program, all equity awards outstanding and held by a non-employee director will vest in full immediately prior to the occurrence of a change in control. No Initial Grants or Annual Grants
were made to our directors during fiscal year 2015, although we did grant options to our directors in connection with our initial public offering as described in more detail below. In March </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=618315,FOLIO='19',FILE='DISK122:[16ZBA1.16ZBA49201]DM49201A.;4',USER='BKYNARD',CD='26-APR-2016;12:50' -->
<A NAME="page_dm49201_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>2016,
the Director Compensation Program was amended to increase the Initial Grant to be an option to purchase 20,000 shares and the Annual Grant to be an option to purchase 10,000 shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
fiscal 2015, prior to our initial public offering, our board of directors granted options to purchase shares of our common stock to each independent director pursuant to our 2008 Long
term Incentive Plan, as amended. In March 2015, we granted to each of Drs. Siegall and Goodman an option to purchase 4,000 shares of our common stock and Mr.&nbsp;Alleva an option to purchase 2,666
shares of our common stock, in consideration for their service as independent directors on our board and each having an exercise price equal to $6.15. In June 2015, we granted to (i)&nbsp;each of
Drs. Powell and Siegall an option to purchase 6,666 shares of our common stock, (ii)&nbsp;each of Drs. Jones and Winkler and Mr.&nbsp;Mathers an option to purchase 4,000 shares of our common
stock, (iii)&nbsp;Dr.&nbsp;Goodman an option to purchase 13,333 shares of our common stock and (iv)&nbsp;Mr.&nbsp;Alleva an option to purchase 8,000 shares of our common stock, all having an
exercise price equal to $6.45. Each option grant made to our independent directors was immediately vested and exercisable with respect to 20% of the shares underlying the option and the remaining
shares vest and become exercisable in substantially equal installments every six months over four years, subject to continued service. In the event of a change of control while an independent director
is still providing services to us, the options held by the independent director will become fully vested and exercisable immediately prior to such change in control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the pricing of our initial public offering in October 2015, each of Drs. Powell, Jones and Winkler and Mr.&nbsp;Mathers was granted an option to purchase 7,200 shares of our
common stock, Mr.&nbsp;Alleva was granted an option to purchase 10,533 shares of our common stock and Dr.&nbsp;Siegall was granted an option to purchase 12,000 shares of our common stock, each
having an exercise price per share equal to $7.00 per share. The options vest and become exercisable in substantially equal installments on each of the first three anniversaries of the applicable
grant date, subject to continued service through each applicable vesting date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
reimburse all of our non-employee directors for all reasonable and customary business expenses incurred providing services to us in accordance with Company policy. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2015 Director Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information for the year ended December&nbsp;31, 2015 regarding the compensation awarded to, earned by
or paid to our non-employee directors: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:31pt;"><FONT SIZE=1><B>Name(1)

<!-- COMMAND=ADD_SCROPPEDRULE,31pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned or<BR>
Paid in Cash ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards<BR>
($)(1)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Powell, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65,064</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,564</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elaine V. Jones, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,227</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63,852</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward Mathers</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,227</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65,102</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matthew Winkler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,227</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61,977</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,438</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,962</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>161,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clay B. Siegall, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>109,049</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>166,862</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corey Goodman, Ph.D.(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>79,547</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>112,547</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the Option Awards column represent the grant date fair value of the stock options granted to the non-employee members of our board
of directors during 2015 as computed in accordance with ASC Topic 718, excluding the impact of estimated forfeitures related to service-based vesting provisions. The assumptions used in calculating
the grant date fair value of the stock options reported in the Option Awards column are set forth in Note&nbsp;8 to the audited financial statements included in our Annual Report on Form&nbsp;10-K
filed on March&nbsp;29, 2016. Note that the amounts reported in this column reflect the accounting cost for these stock options, and </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=180502,FOLIO='20',FILE='DISK122:[16ZBA1.16ZBA49201]DM49201A.;4',USER='BKYNARD',CD='26-APR-2016;12:50' -->
<A NAME="page_dm49201_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<UL>

<P style="font-family:times;"><FONT SIZE=2>do
not correspond to the actual economic value that may be received by the non-employee members of our board of directors from the options.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2015, our non-employee directors held the following outstanding options to purchase our common stock: </FONT></DD></DL>
 </DIV>
<DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="97pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Underlying<BR>
Outstanding Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Powell, Ph.D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elaine V. Jones, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward Mathers</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matthew Winkler, Ph.D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence Alleva</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,532</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clay Siegall, Ph.D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,885</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corey Goodman, Ph.D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,948</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>Our
non-employee directors did not hold any other outstanding equity awards as of December&nbsp;31, 2015.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Effective
July&nbsp;10, 2015, Dr.&nbsp;Goodman resigned from our board of directors and joined our Scientific Advisory Board as Chairman. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=88867,FOLIO='21',FILE='DISK122:[16ZBA1.16ZBA49201]DM49201A.;4',USER='BKYNARD',CD='26-APR-2016;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do49201_1_22"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do49201_executive_officers"> </A>
<A NAME="toc_do49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding our executive officers as of March&nbsp;31, 2016. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul Lammers, M.D., M.Sc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director, President and Chief Executive Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miguel Barbosa, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vincent O'Neill, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Alan Fuhrman</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Casi DeYoung</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Business Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jon Irvin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Vice President of Finance</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Lammers'
biographical information is set forth in "</FONT><FONT SIZE=2><I>Proposal No.&nbsp;1&#151;Election of Directors"</I></FONT><FONT SIZE=2> in this proxy
statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Miguel Barbosa, Ph.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Barbosa has served as our Chief Scientific Officer since September 2015. From April 2015 to September
2015,
Dr.&nbsp;Barbosa served as an Executive in Residence, Therapeutic Innovation, at Johnson&nbsp;&amp; Johnson Innovation, a pharmaceutical company and part of The Johnson&nbsp;&amp; Johnson Family of
Companies ("J&amp;J") where he led the identification and development of new research and development and business models. Previously, Dr.&nbsp;Barbosa served as Vice President, Immunology
Research&nbsp;&amp; External Innovation, from June 2010 to March 2015 and as Vice President, Immunology Research, from June 2009 to June 2010 at Janssen Research&nbsp;&amp; Development L.L.C., a J&amp;J
company. From 2005 to 2009, Dr.&nbsp;Barbosa served in various roles, including Vice President, Discovery Research, at Centocor Research&nbsp;&amp; Development,&nbsp;Inc., a J&amp;J company.
Dr.&nbsp;Barbosa received a B.S. in Genetics from the University of California, Davis, and a Ph.D. in Microbiology&nbsp;&amp; Immunology from the University of California, Los Angeles. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vincent O'Neill, M.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;O'Neill has served as Chief Medical Officer since April 2016. He previously served as the Chief Medical
Officer of
Exosome Diagnostics, a healthcare company, from June 2014 to March 2016. From June 2012 to May 2014, Dr.&nbsp;O'Neill served as the Global Head of Personalized Medicine and Companion Diagnostics at
Sanofi&nbsp;S.A., a multinational pharmaceutical company. Before that, Dr.&nbsp;O'Neill was employed as a Group Director at Genentech,&nbsp;Inc. from February 2009 to June 2012.
Dr.&nbsp;O'Neill has also served at GlaxoSmithKline, Beatson Oncology Centre, F. Hoffmann La-Roche and the University of Glasgow. Dr.&nbsp;O'Neill holds a BSc (Hons), MBChB and an M.D. from the
University of Glasgow. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alan Fuhrman.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Alan Fuhrman has served as our Chief Financial Officer since September 2015. Mr.&nbsp;Fuhrman previously served as the
Chief
Financial Officer of Ambit Biosciences Corporation, a biopharmaceutical company, from October 2010 through the company's initial public offering in 2013 and until its sale to Daiichi Sankyo for up to
$410&nbsp;million. Prior to this role, Mr.&nbsp;Fuhrman served as Chief Financial Officer of Naviscan,&nbsp;Inc., a privately-held medical imaging company, from November 2008 until September
2010, and as Chief Financial Officer of Sonus Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, from September 2004 until August 2008. Mr.&nbsp;Fuhrman is a member of the board of directors of
Loxo Oncology,&nbsp;Inc. Earlier in Mr.&nbsp;Fuhrman's career he practiced as a CPA with Coopers and Lybrand. Mr.&nbsp;Fuhrman received a B.S. in both Business Administration and Agricultural
Economics from Montana State University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Casi DeYoung.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;Casi DeYoung has served as our Chief Business Officer since March 2014. From May 2008 to December 2013,
Ms.&nbsp;DeYoung
served as the Vice President of Business Development for Reata Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company. Previously, Ms.&nbsp;DeYoung served as the Vice President of Business
Development for ODC Therapy,&nbsp;Inc., an immunotherapy company. From 2000 to 2005, Ms.&nbsp;DeYoung served in various roles, including the Director of Global Oncology Operations, for EMD
Pharmaceuticals,&nbsp;Inc., the U.S. affiliate of Merk KGaA, a global </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=102523,FOLIO='22',FILE='DISK122:[16ZBA1.16ZBA49201]DO49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_do49201_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>healthcare
company. Ms.&nbsp;DeYoung received a B.S. in Chemistry from Southwestern University and an M.B.A. from the University of Texas at Austin. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jon Irvin.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Jon Irvin has served at our company since November 2012, first as a Chief Financial Officer Consultant with
Bridgepoint
Consulting,&nbsp;LLC, or Bridgepoint, a consulting firm providing
financial consulting assistance to various organizations, and then as our employee beginning in April 2013. Mr.&nbsp;Irvin currently serves as our Vice President of Finance. From December 2010 to
March 2012, Mr.&nbsp;Irvin was an independent consultant in Austin, Texas. From September 2005 to December 2010, Mr.&nbsp;Irvin served as the Chief Executive Officer and Vice President of Finance
for Voxpath Networks,&nbsp;Inc., a telecommunications and intellectual property company. Previously, Mr.&nbsp;Irvin held various finance positions at Reddwerks Corporation, a software company,
Esoterix,&nbsp;Inc., a medical labs company, Topaz Technologies, a pharmaceutical software company, and BioNumerik Pharmaceuticals,&nbsp;Inc., a pharmaceutical company. Mr.&nbsp;Irvin was
previously an accountant with Price Waterhouse and Ernst&nbsp;&amp; Young. Mr.&nbsp;Irvin received a B.S. in Accounting from the University of Illinois. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=732382,FOLIO='23',FILE='DISK122:[16ZBA1.16ZBA49201]DO49201A.;3',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq49201_1_24"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq49201_executive_compensation"> </A>
<A NAME="toc_dq49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a discussion and analysis of compensation arrangements of our named executive officers ("NEOs"). As an "emerging
growth company" as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable
to emerging growth companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
seek to ensure that the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of
individual performance and near-term corporate targets as well as long-term business objectives. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
NEOs for fiscal year 2015 were as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Paul Lammers, M.D., M.Sc., President and Chief Executive Officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Miguel Barbosa, Ph.D., Chief Scientific Officer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Alan Fuhrman, Chief Financial Officer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Barbosa
and Mr.&nbsp;Fuhrman each commenced employment with us in September 2015. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2015 Summary Compensation Table  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows information regarding the compensation of our named executive officers for services performed in the year
ended December&nbsp;31, 2015. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:102pt;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,102pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Paul Lammers, M.D., M.Sc.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>387,625</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>135,700</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>1,045,503</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>128,885</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>10,600</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>1,708,313</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2014</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>375,829</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>390,780</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>11,275</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>777,884</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miguel Barbosa, Ph. D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
74,038</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
84,902</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
1,354,768</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
21,689</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
16,583</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
1,551,980</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Alan Fuhrman</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
86,250</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
825,840</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
24,425</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
25,407</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
961,922</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Financial Officer</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amount reported in the Bonus column for Dr.&nbsp;Lammers represents the one-time discretionary bonus we paid to Dr.&nbsp;Lammers in July 2015 and
for Dr.&nbsp;Barbosa represents the portion of the sign-on bonus we paid to him in January 2016 that was earned in 2015, pursuant to the terms and conditions of his employment agreement with us. The
remaining portion of Dr.&nbsp;Barbosa's sign-on bonus $245,673 will be earned by Dr.&nbsp;Barbosa if he remains our employee through September&nbsp;28, 2016. Please see the description of
Dr.&nbsp;Lammers one-time discretionary bonus in "Narrative to Summary Compensation Table and Outstanding Equity Awards at 2015 Fiscal Year EndTerms and Conditions of Annual Bonuses" below and
Dr.&nbsp;Barbosa's sign-on bonus in "Narrative to Summary Compensation Table and Outstanding Equity Awards at 2015 Fiscal Year EndTerms and Conditions of Employment Arrangements with our NEOs"
below.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the option awards column, amounts shown represents the grant date fair value of stock options granted during fiscal year 2015 as calculated in
accordance with ASC Topic 718, excluding the impact of estimated forfeitures related to service-based vesting provisions. See Note&nbsp;8 to the financial statements included in our Annual Report on
Form&nbsp;10-K filed on March&nbsp;29, 2016 for the assumptions used in calculating this amount. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=493517,FOLIO='24',FILE='DISK122:[16ZBA1.16ZBA49201]DQ49201A.;5',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_dq49201_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the Non-Equity Incentive Plan Compensation column represent the annual cash bonuses earned by our NEOs pursuant to the achievement
of certain performance objectives in 2015, which were paid in early 2016. Please see the descriptions of the NEOs' annual performance cash bonuses in "Narrative to Summary Compensation Table and
Outstanding Equity Awards at 2015 Fiscal Year EndTerms and Conditions of Annual Bonuses" below.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the All Other Compensation column represent: for Dr.&nbsp;Lammers, 401(k) plan matching contributions; for Dr.&nbsp;Barbosa,
moving reimbursements we paid to Dr.&nbsp;Barbosa, pursuant to his employment agreement, in connection with his relocation to the Austin, Texas area in September 2015, including $1,346 for travel
expenses, $754 for moving expenses and $14,483 for temporary housing expenses; and for Mr.&nbsp;Fuhrman, moving reimbursements we paid to Mr.&nbsp;Fuhrman, pursuant to his employment agreement, in
connection with his relocation to the Austin, Texas area in September 2015, including $3,768 for travel expenses, $13,403 for moving expenses and $8,236 for temporary housing expenses. Please see the
descriptions of Dr.&nbsp;Barbosa's and Mr.&nbsp;Fuhrman's relocation reimbursements pursuant to their employment agreements in "Narrative to Summary Compensation Table and Outstanding Equity
Awards at 2015 Fiscal Year EndTerms and Conditions of Employment Arrangements with our NEOs" below.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Outstanding Equity Awards at 2015 Fiscal Year End  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth all outstanding equity awards held by each of the named executive officers as of December&nbsp;31,
2015. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
(#) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vesting<BR>
Commencement<BR>
Date(1) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Paul Lammers, M.D., M.Sc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/4/2009</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,565</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/31/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/10/2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/10/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/6/2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,607</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,639</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/10/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/1/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5/1/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,201</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>112,465</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/4/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/30/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/30/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miguel Barbosa, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/28/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
284,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
7.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/30/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Alan Fuhrman</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/8/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
167,180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
7.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/30/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Except
as otherwise noted, the shares subject to the options shall vest and become exercisable as to 1/4th&nbsp;of the shares subject to the option on the
first anniversary of the vesting commencement date, and thereafter as to 1/48th&nbsp;of the shares subject to such option on each monthly anniversary of the vesting commencement date, such that all
shares subject to the option will be vested on the fourth anniversary of the vesting commencement date, subject to the holder continuing to provide services to us through such vesting date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
shares subject to the option shall vest and become exercisable as to 1/4th&nbsp;of the shares subject to the option on the vesting commencement date,
and thereafter as to 1/48th&nbsp;of the shares subject to such option on each monthly anniversary of the vesting commencement date, such that all shares subject to the option will be vested on the
third anniversary of the vesting commencement date, subject to the holder continuing to provide services to us through such vesting date. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=125155,FOLIO='25',FILE='DISK122:[16ZBA1.16ZBA49201]DQ49201A.;5',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_dq49201_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
shares subject to the option vest and become exercisable as to 1/48th&nbsp;of the shares subject to such option on each monthly anniversary of the
vesting commencement date, such that all shares subject to the option will be vested on the fourth anniversary of the vesting commencement date, subject to the holder continuing to provide services to
us through such vesting date.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Narrative to 2015 Summary Compensation Table and Outstanding Equity Awards at 2015 Fiscal Year End  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Terms and Conditions of Employee Arrangements with our NEOs  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into agreements with each of the NEOs in connection with his or her employment with us. These agreements set forth the
terms and conditions of employment of each named executive officer, including base salary, initial stock option grants, and standard employee benefit plan participation. Our board of directors or the
compensation committee reviews each NEO's base salary from time to time to ensure compensation adequately reflects the NEO's qualifications, experience, role and responsibilities. Each of the NEOs are
also subject to certain confidentiality, non-competition, non-solicitation and arbitration restrictive covenants. For fiscal year 2015, Dr.&nbsp;Lammers' annual base salary was $387,625 Miguel
Barbosa's base salary was $350,000 and Alan Fuhrman's annual base salary was $325,000. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Mr.&nbsp;Fuhrman's employment agreement, we reimbursed Mr.&nbsp;Fuhrman for his reasonable and necessary documented moving expenses, including the incidental expenses to
the sale of his primary residence in Escondido, California and the purchase of his primary residence in the Austin, Texas area (which amounted to a total of $25,407 in fiscal 2015). These relocation
expenses will not be earned until September&nbsp;8, 2016, and if Mr.&nbsp;Fuhrman resigns his employment with us on or prior to September&nbsp;8, 2016, he will be required to repay us in full
for all of the relocation expenses we reimbursed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Dr.&nbsp;Barbosa's employment agreement, we reimbursed Dr.&nbsp;Barbosa for his reasonable and necessary documented moving expenses, including the incidental expenses to
the sale of his primary residence in San Diego, California and the purchase of his primary residence in the Austin, Texas area (which amounted to a total of $16,583 in fiscal 2015). The relocation
expenses will not be earned until September&nbsp;28, 2016, and if Dr.&nbsp;Barbosa resigns his employment with us on or prior to such date, he will be required to repay us in full for all of the
relocation expenses we reimbursed. In addition, pursuant to his employment agreement, Dr.&nbsp;Barbosa was awarded a sign-on bonus of $330,575 in connection with his commencement of employment with
us, which was paid to him in January 2016. The signing bonus is subject to claw back if Dr.&nbsp;Barbosa's employment with us is terminated for cause or partial claw back if he voluntarily
terminates employment, in each case, prior to September&nbsp;28, 2016. As a result, Dr.&nbsp;Barbosa earned $84,902 of the sign-on bonus based on his service in 2015 from September&nbsp;28
through December&nbsp;31. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with our initial public offering in October 2015, we entered into change in control severance agreements with each of our NEOs that provide for severance payments and
benefits upon certain qualifying terminations of employment. Pursuant to the terms of the change in control severance agreements, in the event an NEO's employment is terminated by us other than for
"cause" or the executive experiences a "constructive termination" (each as defined below), then the NEO will receive as severance nine months (or 12&nbsp;months in the case of Dr.&nbsp;Lammers) of
base salary in a single cash lump sum payment and up to nine months (or 12&nbsp;months in the case of Dr.&nbsp;Lammers) of healthcare continuation coverage premium reimbursement; provided, that if
the termination or resignation occurs within the period commencing on a "change in control" (as defined below) and ending 12&nbsp;months after a change in control, the severance will consist of
12&nbsp;months (or 18&nbsp;months in the case of Dr.&nbsp;Lammers) of base salary paid in a single cash lump sum, 100% (or 150% in the case of Dr.&nbsp;Lammers) of the executive's target bonus
paid in a single cash lump sum, up to 12&nbsp;months (or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=174129,FOLIO='26',FILE='DISK122:[16ZBA1.16ZBA49201]DQ49201A.;5',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_dq49201_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>18&nbsp;months
in the case of Dr.&nbsp;Lammers) of healthcare continuation coverage premium reimbursement and full vesting acceleration for each stock option and other equity award held by the
NEO. The NEO must timely deliver an effective release of claims to us in order to be eligible for the foregoing severance benefits. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the change in control severance agreements, "cause" means (i)&nbsp;the conviction of the NEO by a court of competent jurisdiction of a crime involving moral turpitude;
(ii)&nbsp;the commission, or attempted commission, by the NEO of an act of fraud on us; (iii)&nbsp;the misappropriation, or attempted misappropriation, by the NEO of any of our funds or property;
(iv)&nbsp;the failure by the NEO to perform in any material respect his or her obligations under the terms of his or her agreement, which such failure has gone unremedied within 10&nbsp;days after
we provide the NEO with written notice of such failure; (v)&nbsp;the knowing engagement by the NEO, without the written approval of our board of directors, in any direct, material conflict of
interest with us without compliance with our conflict of interest policy; (vi)&nbsp;the knowing engagement by the NEO, without written approval of our board of directors, in any activity which
competes with our business or which would result in a material injury to us or which otherwise violates any provision of his or her agreement, employment agreement or any confidentiality agreement; or
(vii)&nbsp;the knowing engagement by the NEO in any activity that would constitute a material violation of the provisions of our business ethics policy, employee handbook or similar policies, if
any, then in effect. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the change in control severance agreements, "constructive termination" means the NEO's resignation from all positions he or she then holds with us if: (i)&nbsp;without
the NEO's prior written consent, (a)&nbsp;there is a material diminution in his or her duties and responsibilities with us; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that a
change in title or reporting relationship will not be a constructive termination; (b)&nbsp;there is a material reduction of the NEO's
then-existing base salary; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that a material reduction in his or her base salary
pursuant to a salary reduction program affecting all or substantially all of our employees and that does not adversely affect the NEO to a greater extent than other similarly situated employees will
not be a constructive termination; or (c)&nbsp;the NEO is required to relocate his or her primary work location to a facility or location that would increase his or her
one-way commute distance by more than 50 miles from his or her primary work location as of immediately prior to such change, (ii)&nbsp;the NEO provides written notice outlining such conditions, acts
or omissions to us within 30&nbsp;days immediately following such material change or reduction, (iii)&nbsp;such material change or reduction is not remedied by us within 30&nbsp;days following
our receipt of such written notice and (iv)&nbsp;the NEO's resignation is effective not later than 30&nbsp;days after the expiration of such 30&nbsp;day cure period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the change in control severance agreements, "change in control" generally means (i)&nbsp;the transfer or exchange in a single transaction or series of related
transactions by our stockholders of more than 50% of our voting stock to a person or group; (ii)&nbsp;a change in the composition of our board of directors over a two-year period such that 50% or
more of the members of the board of directors were elected through one or more contested elections; (iii)&nbsp;a merger, consolidation, reorganization or business combination in which we are
involved, directly or indirectly, other than a merger, consolidation, reorganization or business combination which results in our outstanding voting securities immediately before the transaction
continuing to represent a majority of the voting power of the acquiring company's outstanding voting securities and after which no person or group beneficially owns 50% or more of the outstanding
voting securities of the surviving entity immediately after the transaction; or (iv)&nbsp;the sale, exchange, or transfer of all or substantially all of our assets. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Terms and Conditions of Annual Bonuses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For 2015, all of the NEOs were eligible for cash performance-based bonuses pursuant to the achievement of certain performance
objectives. The performance targets are approved annually by our board of directors. When determining the 2015 performance bonus program for the NEOs, the board </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=30,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=212565,FOLIO='27',FILE='DISK122:[16ZBA1.16ZBA49201]DQ49201A.;5',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_dq49201_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
directors set certain performance goals, using a mixture of performance objectives after receiving recommendations from the compensation committee and input from our Chief Executive Officer. These
performance objectives included certain financial, organizational, clinical, intellectual property and development measures. After determining performance targets, each performance target is given a
different weight when determining the overall bonus amount based on the importance to the success of the Company for each performance target. For fiscal year 2015, the financial performance targets
were weighted at 45%, the organizational and clinical targets were each weighted at 20% and the intellectual property and development targets were each weighted at 7.5%. For each of these performance
targets under the annual bonus program, the board of directors set general performance goals, but there was no minimum or maximum achievement for each performance target; instead, the board of
directors weighed the achievement, partial achievement or non-achievement for each performance target when
deciding the overall achievement level. These performance goals were not expected to be attained based on average or below-average performance. The board of directors intended for the performance
targets to require significant effort on the part of the NEOs and, therefore, set these targets at levels they believed would be difficult to achieve, such that average or below-average performance
would not satisfy these targets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
NEO's target bonus opportunity is expressed as a percentage of base salary which can be achieved by meeting the corporate performance goals. For each of the NEOs, the compensation
committee (or, for Dr.&nbsp;Lammers, the board of directors) originally set these target percentages and review them annually to ensure they are adequate, and, while reviewing these target
percentages the compensation committee (or, for Dr.&nbsp;Lammers, the board of directors) does not follow a formula but rather uses the factors as general background information prior to determining
the target bonus opportunity rates for the participating NEOs. The compensation committee (or, for Dr.&nbsp;Lammers, the board of directors) sets these rates based on each participating executive's
experience in his role with the company and the level of responsibility held by each executive, which the board of directors believes directly correlates to his ability to influence corporate results.
For 2015, the board of directors used a guideline target bonus opportunity of 35% for Dr.&nbsp;Lammers and 25% for Dr.&nbsp;Barbosa and Mr.&nbsp;Fuhrman (pro-rated for their partial service in
2015). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate
goals and performance targets are reviewed and approved by the compensation committee (or, for Dr.&nbsp;Lammers, the board of directors) prior to any allocation of the annual
bonuses. In early 2016, the compensation committee (or, for Dr.&nbsp;Lammers, the board of directors) reviewed our 2015 company-wide performance with respect to determining bonuses for executive
officers and determined achievement of the performance goals at 113%. Following its review and determinations, the compensation committee (or, for Dr.&nbsp;Lammers, our board of directors) awarded
2015 cash bonuses to the NEOs of $128,885 for Dr.&nbsp;Lammers, $21,689 for Dr.&nbsp;Barbosa and $24,425 for Mr.&nbsp;Fuhrman, which was equal to 113% of their target bonus amount.
Dr.&nbsp;Barbosa's and Mr.&nbsp;Fuhrman's bonuses were each pro-rated for their partial service in 2015. The NEOs' 2015 bonuses are set forth in the "2015 Summary Compensation Table" above. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in July 2015, at the recommendation of our compensation committee, our board of directors approved a one-time discretionary performance bonus to Dr.&nbsp;Lammers equal to
$135,700. Dr.&nbsp;Lammers' one-time discretionary bonus is set forth in the "2015 Summary Compensation Table" above. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Terms and Conditions of Equity Award Grants  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of our NEOs received an option to purchase our common stock in fiscal year 2015. The table above entitled "Outstanding Equity
Awards at 2015 Fiscal Year End" describes the material terms of other option awards made in past fiscal years to our NEOs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=31,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=269718,FOLIO='28',FILE='DISK122:[16ZBA1.16ZBA49201]DQ49201A.;5',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<A NAME="page_dq49201_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2015, we granted Dr.&nbsp;Lammers an option to purchase 20,000 shares of our common stock having an exercise price per share equal to $6.15. The option vests and becomes
exercisable as to 25% of the shares subject to the option on January&nbsp;1, 2016, and as to 1/48th&nbsp;of the shares subject to the option on each monthly anniversary thereafter, subject to
Dr.&nbsp;Lammers continuing to provide services to us through such vesting date. In June 2015, we awarded Dr.&nbsp;Lammers another option to purchase 112,885 shares of our common stock having an
exercise price per share equal to $6.45. The option vests and becomes exercisable as to 1/48th&nbsp;of the shares subject to the option on each monthly anniversary of May&nbsp;1, 2015, subject to
Dr.&nbsp;Lammers continuing to provide services to us through such vesting date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with our initial public offering in October 2015 and pursuant to Dr.&nbsp;Barbosa's and Mr.&nbsp;Fuhrman's employment agreements, each of Drs. Lammers and Barbosa and
Mr.&nbsp;Fuhrman were granted an option to purchase 76,666, 284,206 and 167,180 shares of our common stock, respectively, having an exercise price per share equal to $7.00. The options vest and
become exercisable as to 25% of the shares subject to the option on the first anniversary of the pricing of the offering for Dr.&nbsp;Lammers and the commencement of employment for
Dr.&nbsp;Barbosa and Mr.&nbsp;Fuhrman, and as to 1/48th&nbsp;of the shares subject to the option on each monthly anniversary thereafter, subject to the NEOs continuing to provide services to us
through such vesting date. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Terms and Conditions of 401(k) Plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our U.S. eligible employees, including our NEOs, participate in our 401(k) plan. Enrollment in the 401(k) plan is automatic for
employees who meet eligibility requirements unless they decline participation. The 401(k) plan is intended to qualify under Section&nbsp;401(k) of the Internal Revenue Service Code of 1986, as
amended, so that contributions to the 401(k) plan by employees or by us, and the investment earnings thereon, are not taxable to the employees until withdrawn from the 401(k) plan, and so that
contributions by us, if any, will be deductible by us when made. Under the 401(k) plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit and to
have the amount of such reduction contributed to the 401(k) plan. Under the 401(k), for fiscal year 2015, we provide matching contributions of $0.50 per dollar up to 8% of an employee's compensation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=32,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=485305,FOLIO='29',FILE='DISK122:[16ZBA1.16ZBA49201]DQ49201A.;5',USER='DNICHOL',CD='26-APR-2016;12:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds49201_1_30"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds49201_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_ds49201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information relating to the beneficial ownership of our common stock as of March&nbsp;31, 2016
by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors and nominees for director; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our NEOs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all directors, nominees and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares beneficially owned by each entity, person, director, nominee or executive officer is determined in accordance with the rules of the SEC, and the information is not
necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment
power as well as any shares that the individual has the right to acquire within 60&nbsp;days of March&nbsp;31, 2016 through the exercise of stock options or other rights. Except as otherwise
indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock held by that person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage of shares beneficially owned is computed on the basis of 20,830,555 shares of our common stock outstanding as of March&nbsp;31, 2016. Shares of our common stock that a
person has the right to acquire within 60&nbsp;days of March&nbsp;31, 2016 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not
deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless
otherwise indicated below, the address for each beneficial owner listed is c/o Mirna Therapeutics,&nbsp;Inc., at 2150 Woodward Street, Suite&nbsp;100, Austin, Texas 78744. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Beneficial Ownership </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:139pt;"><FONT SIZE=1><B>Name and Address of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,139pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Outstanding<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Exercisable<BR>
Within 60 Days </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Beneficial<BR>
Ownership </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>5% and Greater Stockholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sofinnova Venture Partners VIII,&nbsp;L.P.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,974,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,974,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities Associated with New Enterprise Associates(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,974,811</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,974,811</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pfizer&nbsp;Inc.(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,497,586</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,497,586</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancer Prevention and Research Institute of Texas(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,395,010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,395,010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Franklin Resources(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,428,571</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,428,571</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FMR&nbsp;LLC(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,428,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,428,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eastern Capital Limited(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,118,741</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,118,741</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=33,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=714513,FOLIO='30',FILE='DISK122:[16ZBA1.16ZBA49201]DS49201A.;11',USER='BKYNARD',CD='27-APR-2016;09:52' -->
<A NAME="page_ds49201_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Beneficial Ownership </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:139pt;"><FONT SIZE=1><B>Name and Address of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,139pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Outstanding<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Exercisable<BR>
Within 60 Days </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Beneficial<BR>
Ownership </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers, Directors and Nominees</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul Lammers, M.D., M.Sc.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,787</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>197,339</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>216,126</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Alan Fuhrman</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miguel Barbosa, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Powell, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,974,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,976,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elaine V. Jones, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward Mathers</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matthew Winkler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>649,175</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>650,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,025</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,824</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clay B. Siegall Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Greenleaf</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Perry Nisen M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All directors, nominees and executive officers as a group (14 persons)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,655,534</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>280,885</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,936,419</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Indicates
beneficial ownership of less than 1% of the total outstanding shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
reported on Schedule&nbsp;13D, filed with the SEC on October&nbsp;8, 2015 by Sofinnova Ventures Partners VIII,&nbsp;L.P. ("SVP VIII"), Sofinnova
Management VIII, L.L.C. ("SM VIII"), Dr.&nbsp;Srinivas Akkaraju, Dr.&nbsp;Michael F. Powell, Dr.&nbsp;James I. Healy, and Dr.&nbsp;Anand Mehra. SM VIII is the general partner of SVP VIII. The
individual Managers, or the Managing Members, of SVP VIII are Michael Powell, James Healy, Srinivas Akkaraju and Anand Mehra. The Managers share voting and dispositive power with regard to the shares
held directly by SVP VIII. The address of SVP VIII is 3000 Sand Hill Road, Bldg. 4, Suite&nbsp;250, Menlo Park, CA 94025.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
reported on Schedule&nbsp;13D, filed with the SEC on October&nbsp;14, 2015, by New Enterprise Associates 14,&nbsp;L.P. ("NEA 14"), NEA Partners
14,&nbsp;L.P. ("NEA Partners 14"), NEA 14&nbsp;GP,&nbsp;LTD ("NEA 14&nbsp;LTD"), M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Krishna S.
Kolluri, David M. Mott, Scott D. Sandell, Peter W. Sonsini, Ravi Viswanathan and Harry R. Weller. The shares directly held by NEA 14 are indirectly held by NEA Partners 14, the sole general partner of
NEA 14. NEA 14&nbsp;LTD is the sole general partner of NEA Partners 14. The individual Managers, or the Managers, of NEA 14&nbsp;LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Ryan D.
Drant, Anthony A. Florence, Jr., Patrick J. Kerins, Krishna Kolluri, David M. Mott, Scott D. Sandell, Peter Sonsini, Ravi Viswanathan and Harry R. Weller. The Managers share voting and dispositive
power with regard to shares held directly by NEA&nbsp;14. Also includes 3,294 shares held by certain entities associated with New Enterprise Associates. The address of NEA 14 is 1954 Greenspring
Drive, Suite&nbsp;600, Timonium, MD 21903.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
reported on Schedule&nbsp;13G/A, filed with the SEC on February&nbsp;11, 2016 by Pfizer,&nbsp;Inc. The address for this entity is 235 E.
42nd&nbsp;Street, New York, NY 10017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
reported on Schedule&nbsp;13G, filed with the SEC on October&nbsp;8, 2015, by Cancer Prevention and Research Institute of Texas. The address for this
entity is 1701&nbsp;N. Congress Avenue, Suite&nbsp;6-127 Austin, TX 78701.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
reported on Schedule&nbsp;13G, filed with the SEC on February&nbsp;9, 2016 by Franklin Resources, Inc. ("FRI"), Charles B. Johnson ("Charles
Johnson"), Rupert&nbsp;H. Johnson,&nbsp;Jr. ("Rupert Johnson") and Franklin Advisers, Inc. ("Advisers"). Charles Johnson and Rupert Johnson each own in excess of </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=34,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=516447,FOLIO='31',FILE='DISK122:[16ZBA1.16ZBA49201]DS49201A.;11',USER='BKYNARD',CD='27-APR-2016;09:52' -->
<A NAME="page_ds49201_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>10%
of the outstanding common stock of FRI and are the principal stockholders of FRI. Accordingly, FRI, Charles Johnson and Rupert Johnson may be deemed to be the beneficial owners of securities held
by persons and entities for whom or for which FRI subsidiaries provide investment management services. FRI, Charles Johnson and Rupert Johnson disclaim any pecuniary interest in any of the securities.
The address of FRI, Charles Johnson, Rupert Johnson and Advisers is One Franklin Parkway, San Mateo, CA 94403-1906.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
reported on Schedule&nbsp;13G, filed with the SEC on February&nbsp;12, 2016 by FMR&nbsp;LLC ("FMR"), Abigail P. Johnson ("Ms.&nbsp;Johnson") and
Select Biotechnology Portfolio (the "Portfolio"). Ms.&nbsp;Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR. Accordingly, Ms.&nbsp;Johnson may be
deemed to have voting and investment power over the shares held by FMR. The address of FMR, Ms.&nbsp;Johnson and the Portfolio is 245 Summer Street, Boston, Massachusetts 02210.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
reported on Schedule&nbsp;13G, filed with the SEC on October&nbsp;15, 2015 by Eastern Capital Limited, Portfolio Services&nbsp;Ltd. and Kenneth B.
Dart. Eastern Capital Limited is a Cayman Islands corporation. Portfolio Services&nbsp;Ltd., a Cayman Islands corporation, owns all of the outstanding stock of Eastern Capital Limited. Kenneth B.
Dart is the beneficial owner of all of the outstanding stock of Portfolio Services&nbsp;Ltd. Kenneth B. Dart is a director of both Eastern Capital Limited and Portfolio Services&nbsp;Ltd. The
address for these entities is 10&nbsp;Market Street #773, Camana Bay, Grand Cayman, KY1-9006, Cayman Islands.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of: (i)&nbsp;8,799 shares that may be acquired pursuant to the exercise of stock options within 60&nbsp;days of March&nbsp;31, 2016 by
Mr.&nbsp;Alleva and (ii)&nbsp;4,025 shares held by the Lawrence M. Alleva Profit Sharing Plan.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds49201_section_16(a)_benefici__ds402038"> </A>
<A NAME="toc_ds49201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires the Company's directors and
executive officers, and persons who own more than 10% of a registered class of the Company's equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of
common stock and other equity securities of the Company. Officers, directors and greater than 10% stockholders are required by SEC regulations to furnish the Company with copies of all
Section&nbsp;16(a) forms they file. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company's knowledge, based solely on a review of the copies of such reports furnished to the Company and written representations that no other reports were required, during the
year ended December&nbsp;31, 2015, all Section&nbsp;16(a) filing requirements applicable to our officers, directors and greater than 10% beneficial owners were complied with. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=35,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=719739,FOLIO='32',FILE='DISK122:[16ZBA1.16ZBA49201]DS49201A.;11',USER='BKYNARD',CD='27-APR-2016;09:52' -->
<A NAME="page_ds49201_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds49201_additional_information"> </A>
<A NAME="toc_ds49201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  ADDITIONAL INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Householding of Proxy Materials  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC has adopted rules known as "householding" that permit companies and intermediaries (such as brokers) to deliver one set of
proxy materials to multiple stockholders residing at the same address. This process enables us to reduce our printing and distribution costs, and reduce our environmental impact. Householding is
available to both registered stockholders and beneficial owners of shares held in street name. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Registered Stockholders  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a registered stockholder and have consented to householding, then we will deliver or mail one set of our proxy materials, as
applicable, for all registered stockholders residing at the same address. Your consent will continue unless you revoke it, which you may do at any time by providing notice to the Company's Corporate
Secretary by telephone at (512)&nbsp;901-0900 or by mail at 2150 Woodward Street, Suite&nbsp;1000, Austin, TX, 78744. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a registered stockholder who has not consented to householding, then we will continue to deliver or mail copies of our proxy materials, as applicable, to each registered
stockholder residing at the same address. You may elect to participate in householding and receive only one set of proxy materials for all registered stockholders residing at the same address by
providing notice to the Company as described above. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Street Name Holders  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders who hold their shares through a brokerage may elect to participate in householding, or revoke their consent to participate
in householding, by contacting their respective brokers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds49201_annual_reports"> </A>
<A NAME="toc_ds49201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Annual Reports    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>This proxy statement is accompanied by our Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2015 (the "Form&nbsp;10-K"). The Form&nbsp;10-K includes our audited financial statements. We have filed the Form&nbsp;10-K with the SEC, and it is available free of charge
at the SEC's website at www.sec.gov and on our website at www.mirnarx.com. In addition, upon written request to the Company's Corporate Secretary at 2150 Woodward Street, Suite&nbsp;100, Austin,
Texas 78744, we will mail a paper copy of our Form&nbsp;10-K, including the financial statements and the financial statement schedules, to you free of charge.</B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Other Matters  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the date of this proxy statement, our board of directors knows of no other matters that will be presented for consideration at
the Annual Meeting other than the matters described in this proxy statement. If other matters are properly brought before the Annual Meeting, then proxies will be voted in accordance with the
recommendation of the board of directors or, in the absence of such a recommendation, in accordance with the best judgment of the proxy holder. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>/s/ PAUL LAMMERS<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Paul Lammers, M.D., M.Sc.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Austin,
Texas<BR>
April&nbsp;27, 2016 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=36,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=105158,FOLIO='33',FILE='DISK122:[16ZBA1.16ZBA49201]DS49201A.;11',USER='BKYNARD',CD='27-APR-2016;09:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET - www.proxyvote.com Use the Internet to transmit your voting   instructions and for electronic delivery of information up until 11:59 P.M.   Eastern Time the day before the cut-off date or meeting date. Have your proxy   card in hand when you access the web site and follow the instructions to   obtain your records and to create an electronic voting instruction form.   MIRNA THERAPEUTICS, INC. 2150 WOODWARD STREET, SUITE 100 AUSTIN, TX 78744   ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the   costs incurred by our company in mailing proxy materials, you can consent to   receiving all future proxy statements, proxy cards and annual reports   electronically via e-mail or the Internet. To sign up for electronic   delivery, please follow the instructions above to vote using the Internet   and, when prompted, indicate that you agree to receive or access proxy   materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use   any touch-tone telephone to transmit your voting instructions up until 11:59   P.M. Eastern Time the day before the cut-off date or meeting date. Have your   proxy card in hand when you call and then follow the instructions. VOTE BY   MAIL Mark, sign and date your proxy card and return it in the postage-paid   envelope we have provided or return it to Vote Processing, c/o Broadridge, 51   Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK   INK AS FOLLOWS: E10451-P78446 KEEP THIS PORTION FOR YOUR RECORDS DETACH AND   RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.   MIRNA THERAPEUTICS, INC. The Board of Directors recommends you vote FOR the   following: 1.To elect three Class I directors to hold office until the 2019   Annual Meeting of Stockholders or until their successors are elected.   Nominees: For Withhold AllAll For All Except To withhold authority to vote   for any individual nominee(s), mark &#147;For All Except&#148; and write the number(s)   of the nominee(s) on the line below. ! ! ! 01) 02) 03) Perry Nisen, M.D.,   Ph.D. Matthew Winkler, Ph.D. Peter S. Greenleaf The Board of Directors   recommends you vote FOR the following proposal: For Against Abstain ! ! !   2.To ratify the selection, by the audit committee of our Board of Directors,   of Ernst &amp; Young LLP as the independent registered public accounting firm   of the Company for its fiscal year ending December 31, 2016. NOTE: The   proxies are authorized to vote in their discretion upon such other business   as may properly come before the Annual Meeting or any adjournment or   postponement thereof. ! For address changes and/or comments, please check   this box and write them on the back where indicated. Please indicate if you   plan to attend this meeting. Yes ! No ! Please sign exactly as your name(s)   appear(s) hereon. When signing as attorney, executor, administrator, or other   fiduciary, please give full title as such. Joint owners should each sign   personally. All holders must sign. If a corporation or partnership, please   sign in full corporate or partnership name by authorized officer. Signature [PLEASE   SIGN WITHIN BOX] Date Signature (Joint Owners) Date </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="680" height="880" src="g89922bgi001.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=37,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=723066,FOLIO='',FILE="DISK123:[16ZBA2.16ZBA49202]8992-2-BG_ZBA49202.CHC",USER="DNICHOL",CD='Apr 27 03:10 2016' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting:   The Notice and Proxy Statement and Form 10-K are available at   www.proxyvote.com. E10452-P78446 MIRNA THERAPEUTICS, INC. Annual Meeting of   Stockholders June 29, 2016 8:00 AM This proxy is solicited by the Board of   Directors The stockholder(s) hereby appoint(s) Paul Lammers and Alan Fuhrman,   or either of them, as proxies, each with the power to appoint his substitute,   and hereby authorize(s) them to represent and to vote, as designated on the   reverse side of this ballot, all of the shares of Common Stock of MIRNA   THERAPEUTICS, INC. that the stockholder(s) is/are entitled to vote at the   Annual Meeting of Stockholders to be held at 8:00 AM, EDT on June 29, 2016,   at the offices of Latham &amp; Watkins LLP, 885 Third Avenue, New York, New   York, and any adjournment or postponement thereof, on all matters set forth   on the reverse side and in the discretion of the proxies upon such other   matters as may properly come before the Annual Meeting. This proxy, when   properly executed, will be voted in the manner directed herein. If no such   direction is made, this proxy will be voted in accordance with the Board of Directors'   recommendations. (If you noted any Address Changes/Comments above, please   mark corresponding box on the reverse side.) Continued and to be signed on   reverse side Address Changes/Comments: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="680" height="880" src="g89922bgi002.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=38,EFW="2228438",CP="MIRNA THERAPEUTICS, INC.",DN="1",CHK=635820,FOLIO='',FILE="DISK123:[16ZBA2.16ZBA49202]8992-2-BG_ZBA49202.CHC",USER="DNICHOL",CD='Apr 27 03:10 2016' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g89922bgi001.gif
<DESCRIPTION>G89922BGI001.GIF
<TEXT>
begin 644 g89922bgi001.gif
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M_O___P
M                     "'Y!       +     "H G #  C^ -D)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K
M6+-JW<JUJ]>O8,.*'4NVK-FS:-.J7<NVK=NW<./*G4NWKMV[>//JW<NWK]^_
M@ ,+'DRXL.'#B!,K7LRXL>/'D"-+GDRYLN7+F#-KWLRYL^?/H$.+'DVZM.G3
MJ%.K7LVZM>O7L&/+GDV[MNW;N'/KWLV[M^_?P(,+'TZ\N/'CR),K7\Z\N?/G
MT*-+GTZ]NO7KV+-KW\Z]N_?OX,/^BQ]/OKSY\^C3JU_/OKW[]_#CRY]/O[[]
M^_CSZ]_/O[___P""%0DK[&B#R#G$Y)&'*.=P\L8;>5AR"!UI*"-0+6G<<4@T
MB! HRQ_CL*-)+=W006 DA-!QQX.0I$''(<K\\<8=RNR2!S'L<((*(7>D00PG
M:*R("D_==!/@D2'1,4:.7S"3Q"&H',&),(C\0(HL1U@BBY'LW#$&*CEH0H@6
MRARAB4!YW"&,"E-<D\87&%II20V:\(**"I9\\08B&J#1#1::-)&&+-$(\\<)
MD5A8T#7:L#..D44:J<TY[$3#*#O=C'/.-0)IT\TU(6KC:8&<=A,-IJ-J,TZC
MYS##3JO^(0KS!2>D%J1--(^>RLXUW31:))+ (B1+#FY&(HH01AXR!3N[Q*#-
M-2YP4DNC[*"A!2DN3)N$%D>$R,X;:.RB0@UYC+%DE>>PH@(IQ+#2@2AI_$'(
MN)PD 8D0=]02(BLCN&J0*&.,\P4:S$RA"1KGW-$F%FF\\2<=UV#!S#E:)''$
M'=<<D00JK-20!"ND-%$+&JP@G <J7T R\CAOU(!&-&A <,0A6DP!R4"DN"S*
M$4)$,@ZW32"2QAC4!FOTKDD@@@4OA& A4,X(NL!,-S4(JN@?(V#11(B15'"F
M0%C\H8P+D*@0P[*'LL,* E\0@DH,6)S 2B1-1))$$G>X\ /^&L*P(\L/_K(C
M"H/L,!,#)-N*TH23I-"1 \"[3*'X%_"&.$4:M0@A2PTW8_'&+D<(@P6>VB1!
M"AK**(P(),R<4$L>?$< 20UZCL I.UB@P<X?1RB3A"B>_Y&$,CD0>/31?PB!
MQCA_RW+-%VFP0\P1GAZQ"T%_W,%,F.P(<\3M7?Y!3!+1I-%!](@<<8XL,5BX
MN3)?Y($X,T><H,F3 VVNZSB61$+I.6/HF9<0P0Y"'($0A_@"';K4!%$00@B<
MX 4SOG (7OR %4GHVQLJJ#DT".$0!3P@.Y31A'!%HPG"R,,7E%$#3C2A;7F(
M1BW.\2)V0()@4AJ#*#BA!6V$[GC^1WL;",]!B"F4T$*U2,(XHO&#$N*('6D0
M0A.:X+XD<(D=AWA#$KLAC!CD041:.,<N<C %.G#"!=% Q0_N((1SB$(#I/A"
M#M! "G;4 HT(084&9%&+'/#";_831@UD(2(5[((4/P#=(7AVA H) 4>12\(?
M_C &7GQ,%B,8TCF$,(9SG.->6&#%)Z?P!RQ@01;*$$(T(J>%2*3A"&\X(2M8
M0<5' O%HN!I(-"8FD"52*AK*4 :E"L0,95#K'+KJE*IT%0U?<:I5RF"&+\?!
MC&>]:FK7"*:1EHB06ASB#I" A/PB@0@-16*<WPRG_/)0I8L=XIR0B(0E>"3.
M=RI("S'^>.<Y_Q")?MZ!$/V#Q!W.20=((&*<A-C@A.*9AT,@X@_BM(2W;DE1
MH9PC4T4:QZ,TFBF.<A2C&CT$*<ZQ48R"M*/,T.*C.IK1E9ITI1K=:$EE^M**
MVM0@W1CF4'3J$9[JY!Q%4\85%:*JGA;-4:RZZ6AXT;=H$!(A")+>40GBU(((
MPZ<*F=I GF@04%7$5<3 ZE>-)$RB@H\@W"2JD7)Y$6:(0B#1\%E#1!$X@ESC
MK CAI4'<2A!EB()72A6-,/X8#5%JE9I<NL:!B*%53$D3KJ*,IJ8.P2EFW*Y(
MVE#&J9 )JDC4HE.(<-4XO"H05%@H&M$P530NJEE*:4.:T33^%:= 15F"; JH
MD#(2IT:+UD99JAN6N%XO;X=,H0KD5[V":V8)- YE\'92Q*S%'Z]QT6IVRDC(
MO.(U]D?=5VE#%K1BEL^H>5DN(59MS5SMJ[9+BI$:LU+<I11U;S7,38&W4IPJ
M+*:T*]K6!M8RJ,64,GBQ"V5<0X*BD%0=2<$*8HA*&,(8J8"9D8<(CX,4W9#%
M+HBQ2U3P3Q2RX$4T6;&+X()V:HEBQ>TLT;<_;)@9N[A&+1#!BUI$F!@V(D8D
M>+%C2VB#%-02!H=W40MBD(+ ^O(9)!2EX@:3 A6HX(2)A7$-4BB#%=U !8<^
M:\=:%%88N^ %)Y@A"TOX[1#:,#/^75'AO"<+CA>0$ ;KA%&+#3/8N)E5!BG&
M 0EB7)6Q4A;(+GP6W#H)@Q-<8I<P,AOA-,95LT\N41JA3(IK1((9.&(QZX:)
M"F9P0A/MPG1FF<$,?74:Q[*0!2)V4:B^_5<R82X<*0I5ZDB0@A.[/1,O;H6*
MP>TP1,SH]%LCT0U-\%E'HB"PX$@M(59(BZX".8<EQ$@@9M21';MF![&S'(E=
M$'D<D8B&)H2A#%KYKQ9E+K:W/$V*6@Q)&YK@([C'P67I*<,2,J;4+C1A(4X0
M8TBU8,8?:\'E.O-BX.+F130&GF3!"6/:([30#@GY;RUK0\B<4-0Y(IR'<WP6
M%3\:87C^W=J-ZY4\F+U$A"C:S8IYLD(3K'@JP<'M<4]Z^8^(M@2H![*^P@T.
MYOR&<K!E00I(])K-M:@RM%\=&2,SBY# 906#<NJH,Q'#5&R6Q:/@*FQMJYL4
MP@B1MW.T2TW@6Z.B4)2VFSND73S5P6LGQC500>09^@_>I!@VO6MA"75'.Y[7
MX 3;O4WS/W9JY<PJDIC[[70J7X_@%Y+N+L[QQP:ALLOG.)._<0U?P;676>Y.
M+8ZT$0E.V4D;D!C''T%N9KZ.D$&?C0:'==4@7D)9%)K2<^3!G7C5:P-'F@ N
M*83[JL_Z=1>B;!7'T@@C?VL4\N04*],5(T91Z(L8EB 1+S3^(7A!$T.HW7 N
MWX<DX&L0$A7G4,8,28'O[?IMNP%'Q:4C/!!6?);'3]V5*#U\;TO(_JH@YS;*
M0$@C-5CHIWX#P6:%8PE[AFV<L&>N)A )5CA"%V$(DEG=0V_]PV5"AEH(<@U:
MXE37 &&[(@J:P"C<IPVLP#P"!V+-Y2F8%EQK!0DZ,@Y]<W7"$ F<\%1510RB
MP JWDDSP)GA"E8/WIS+1P D_-D)/-C46 H R9@E/Q&,[:$>)T@W%]"E#<@US
MPU1]4PO7-GV1<457I%$\YTFVI2D\5Q!H>%'19A!N^"IHU4L\Q5,YI5.4,E$'
M@88%8@G^PH<D]88'H89R^#\#,8+^HL!5MD52>5@0A.B&>N@M>#A49F@0E>B(
MAFA;V'5<PZ2&D5B'!$%UO311H@B'5Z2"4R6&Z5%C("%F$:@7!Z>*EJ&'MH57
M,Q&(5D&+EJ@0A,B&TC>(OQ@118*+ Z&+LCB+*@97>NAN$D%=:<41T$5JY"<]
M_J(-AB<0G !X?J,)QT0*D= W)3=,PI!,(X0(_G<0W<40,_8'B%974%5988@0
M*Y@0,680*CA4"<$II."."U%4<*@)F*9V F%LQW@9IE(X?\ E.86%GK1J<(5=
MO&(J0.4KQO1),X1=O+1$9/@JGI19$Q4BFL*0YX (G]5<;U4XW>8H#,:)I1<B
M5E9EV+7^"\5&6^ H-@11"_.8?IM532KS*L;U*:N23!L'<;XB39=2.-3"#"#"
M#">8AXU%3+RP*4+EB0+Q?>IU#:ZR"P=2*1"9*8^%D.,@"KM +:^%AU,#DB-)
M?)AR*DKY76KW6I#0*^"'"OE%C@6)&-I@@G2V0@)!9=RG8F]P)L*@"0DF9M@'
M<L@WCC_H)IR01NP099^E":C "]Y"6 O'"2N7AV?">J:E6$,R)>&5+ERF#<+E
M*E#"*<26(Z[B<?16)'FWC>3H;AWY9./@@YR "![6:[Q0;'P4;\G$5^.@"=*&
MF3O$#&DD"J>R"X1@G)# "K#57I*R;\(I#,EFG'DI:)'0:='^\(/*H EI0)K+
M%U<0]H.44@MCX%:<,)8E)RV= C*']IAP-HW,P ITIYR#1GY)2 J(H'2@MFKF
M-R5WJ1@G*"+*$ D)&')C25?7<"9)6&?G8*!T17*H\ ?70%?1P&"K5V+C0&0"
M(0N4AV3L,&N. J$/MVR+Q@XL=I)=UDN<H%/JQPLCB)FAY2A0TE2H4&E/=HU^
M\P?.LSZ10 S$H'6[%@U_0 J'H*$$)VT#X6DC.@ZTDG2>MB"64'F?Q:0L=@?L
MYRK0)GAN%7P$]U2=)B+LYT#426\%4F#J5Z0^ABEJ9IRDH DJ)YS=XRK= *',
ML&B>!F:-DG0?IROUV'=N10=A.0[^A* )<!J@B:$)I\)ZPR1W?4-7"GHF629O
M=LJ4&8=E$6I]KC*9$H5N N$SEN6I5X<I!CHE9C9FT,9BX;6BKZ*C'?I9UX!]
MV'6-X7>AK%97GFI'@WE_.B=-&2=-/C-S!BH03%JGE+=LW;!]C.4K!NI7*$H,
M_/98&8=M*J@,A- -1:<K5(:BA&F<;K6@A3,B11:AE%*GR^96J6:<I?5'YHJJ
MSF5,BDJ@!CJJ@F,AEY9QUQJ5D2 +EH6HB&%D8.:D2XJ!NQFFP^<\!R>P6E:A
MB;B"3!5LX\ *A]8@&RI<Q, +*B8+A "D^9-CM*)EN] W_C:-8^>3Q2@+_V8J
M/FAXZ3?^$*:B#6,F*LF%;6G'+!&F#'1F"0TF."@+LQ\:G+HT)$X:5;NV1#@F
M8J_"(!>:(QM*8)4%<EB&LE9'"%M59TGWC8PU)" 6K:Z"LOKR*BJVL*B083C6
M*=](;S:R2A&(?>#E<87#)3"6MB&6!QN:3>SBJOXZ&+AHC+U4C/\3(MOD21SE
MMR$2AX6K4VKH;GJ(6X[B*(+KN!_)MQF%*GR[AY(X*D#U/Y."BT6%EIC"<]["
MMYG;MX$8ND4SLUOG-_F'5)K[N 5"B[\2;6;(N1,%5-Z%79&8BL6(N:-"B-"5
MM[M!:GL!K;H+O,;+$L$8$;^8O,?;'EQBEPEQ5:";$%$E/<S^.Q/FY[*I>&$-
M$7X)T8 R$2)5)1$D>!"B4KG-"QBU>X8<*;MT*"*^TKZ<F(:(YDF;PK*TZ+9V
M)+@^Q8>V)8=PR%./V+=%E8Z8R(AOB$S7B(9Z:*R=^#]F>6WUE3]7A(O^NX:.
MFQ"$*(F'&VT0/!!IYVFU*WT?C&X^5;CTAL+I*QC:4 L1- Z'P%4_.$NR( QD
M!F07:F4FLBLP*Y/2PPF$H"LPBPIH!H:]MI\E!Y"V%97=TPTZLF%"54T[>#L0
M1F_=&7#9NV=BZ2U$#(111K-AQJ_2<EZ.L@NB &:]%K&3*0L[IKV'QE7C< =\
MA"#6IPV'8'_=PX G^7W@9BD8ZV_^F%(+BBIG_!IM.$(B[(=H,<9;CF+$8<D*
MA7(EW\4*!S=+ ]B V@!0S$ '4VI'LF \T@-Z:F-MA"(+6/J'^R:3WA1P1%>\
M*XP7*I8NS+"5@I:LE,EW&H:9Q  )&AJQ 2MW%F()BL(N=K1$AU9JGCQCMK4Z
M!O4H$=;"I38X=O)+&;<+8YME(1>L5S1N>7QUHE18Q( (%S> ?NIJL0JI:39"
M^2=D&&9@QT5 8X:%A"!G.?)PR.1JW6!C>1!BP8:%U^!VM>!98VMF*MG"CFEC
M5Y>]<'5H*#NBR9FBFB"3=G)%8Q97TJ9C=O)$0$:?W7EDLA!O0S*J,$P,-B@,
M*Z@E=O+^RG^QIJ9*$ SB9VZTK^K79[M&;!$+I!<6BTL';966B&,6F2@KD!?F
MFMUPL:EG+#";B,G$QO8L;=2)HM@Z436;I4G8AZA MW$UC8GX--0YG^8J8UL5
MI!MG>.::=@'("Z>:@Y4"RIJPC_(W#D/"5)S08*76<!<27!=;..AV5US6#8FX
M0SB2+H(&:E<G"PSR<%R2J<^*M=12;KZF9R$K8Y\%R=%V:NWRH$$=&,HP(=3B
MG4-R"!+U370P0T040]+S!ZQB"6B@B*^3!GGP!H00(XJB"2 B"D%R!R*V(C,J
M$*R0!M>F#'F0!@,Z,G1 !_M)"*Q""-TF(Q!"!S;R1]:&"+C^=@ZD(#^Z6"+.
MTU"O8@E#4EB(P&^D,6CV!UP$ :JX$ES!I0UK''A7I7#GG80EYB\"9\HZ9MCY
MK'H$%W9<<JS4BFYWD,]G\F,.*A"\0 <;=VL>=G#$UG<@''.WYBHX&0F&6@MO
M!7-+"@G\ZEDG^$<,)I:Z5"@>U]=JIF,E5J*)>+'R5'\'HH/89D<ART<XM@O\
MLZ0@@JUV$LD>7BG[^E>2_-&[UISSB0HD2<2ZPF9\Y6/<'8$& F-?A'U%M@O/
MAEVB@ HV+'L"%USH>Q>D< 1-0""(Y )#H@4;D@.$L.6BH T_T $WDP93$"+$
M@ 4QL+K*@#):8']W4D?G@ 6($ W^,4 (LV1I5G((3?!,;Q #NI,C.0 )8LX.
M>? [E+P+MJ0-B7YE=Q-SN_ #%SL%^RS,B# &G! )J<@+.5"@&I #U;./8T R
MZ5D:=^I)9^6,NJ771C)8Q/2Z.95?M< Z U$C%E(CKJ)5,C2YG3+L,&8AL6O0
M V'- J$,884I"K<K!/'$JS),[KU:?5./AYAT,N9<C;*A)WI<R16[T#XI,F24
M!>))87:ZC>)5OK)6T_(KR21NT99M(T3O([0+KM+"U(5C%X7O.+9$TU*,W [M
ME/>*NW4[I>8IZE<TL<A1OTXB@9$\0A"71U #'2!B>!(-*B!*$$0,)] !6' .
M2? % I'^!FF@YP6A\6]06BI@(1X_)1T RH?P ^< )IRB"3GP!S70* $$PS_0
M#5.P\@*!"#DPZX94("ZP)%BD LS0!&\0NCD@] =!""Z@#7>@ 9E$#"ZP"W0P
MZ,B!"EJ2$KL,O0GA/ QQ:T5A::^8'.>@ G?P [V6 V-P ND" 855 '?P!4T
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M 4K$2 -3$*R=PY7-(;7X2!Y$=!O^4J0A-IS( QKN0 ==T2$-KF&',L9PAS<
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M%9B"^>+<YG7>@QT#+) .8JB!!>DR3I@"+!@'8C"Q-\""]  VG,"(D2T]--"
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MDC^H1D)HZP)Z@PY SO8F\\Q%@R2X)V'X 4Z CMU>E"\PL5=B"#)I0T[0 KL
M-=^#.VTXA--\%6(X D1 !<XX7E(@A#%@!J:>0%(X GXQZUDY <-5<V_1AB2(
M!+CC6>QX"(74A%K6!BT@79T66+I) Z/MPX-X@Q7]9&U>&CK($FB[C;=[B F)
M!K/4L;Q!.0)7AB-(&[(8&D1XN\]K-6V^ TB8@L+ :E'Y 6^YPTM/ EG( 5+X
M1T1P<BADA>@8S$4N\VU7VR.[@^.!T7(J5CI88D+8L>U] V0$G$*KECR@@SOI
M!D+ "D+^L!.<J 7F/" TB4A(N!U+0(,\D(5:@%$/E!52-1IE@-$6_(,+R=*;
M,5O^PM6#P$6+V-&B,/<K/0=$.(AHB(0?DPZS8 5A@]%\YW.F\,";B82$20-4
MZ 8^AQ)9@%52;9=X";U:Z ;!K" &RDSS0/@T:,$\@!*T>7=8$0Q(0!JX84\O
MX_:E9_JF=_JGA_JHE_JI!]38.HZ-=*ZB +S8)0IM".B/9-X9ROI.\2_ @CRJ
M1WO+>PQ:0@ZM(HB>&)_L8LBJ&/.5*"*6""]-APD:/@ZW=_O[XL.X3_O!I[O&
MJU7:6HT>_C>[HY^-A#R28I1#T(Y(D.VD7+B-;)6^88:G4*S^U@H,"VN>DOA+
MS4\\2XB.E!^()28/,/K\K"^O6V']DFCY8(F4A Z,EO]+,4U]9I#\QVTG]M&.
M];C]P-#B 0;CNP*X3MG\.K7/-V:4O\MCB&C3ZXD4Y=K\DCF')79@^9!MTD@*
M^E%CQ9J?S@</KY\.9?A;PE?_'.*F+1(5A#$M36B5[:6P]."OR6&A6B"%9ZLY
MDGB6Y@$(8<3H=&/'SI(P4M=(H6+&RJ$P@[LL=8LT<9?!6H?.D2*VJY8P9G>8
M*>MV358T2,S&==P5<9RE72*%H=(FRF$T@Y9J==.&2EDD8I&8\4)TCM>NDNS.
MH>+%25FT<8B(C8MTKM:N:*C&:1+^I4T@*:0#QQG,4XM8+5)<KRV514P4TEHP
M96TT2(J4MHK*6&G3Q$F6)F%3\S 3=DT9,U+"\B1D)JN;+(/1:D5C3.J<P3]I
M1>T*RBQKK5J!15V+I(P8.V'1#D5FIS$:,5E&2<GBQ>L:JUVHH@F+:/ W\.#"
MAQ,O;OPX\N3*ES-O[OPY].C2IU.O;OTZ=N6[=G$BRTX9)U+1+&ECQXD8)W:[
MV++3)$N4)F5(SUV-QJL]3$[,V$7RCM!K'LJ< PDIFI!B$#.B1).>-I88)(M<
M=,AB223WZ;>;-KP0DU,W$E9HD'[,I(<0';5$DI,V&+$C'CNRH")*+=K4PDYA
M^RUUEH#^G-326G^AV6;>@J((&2-__G5S55*:8,8,*NST%=I<,[)3%6:[1*;5
M3=&(<I!3ZB4E"QV\;'FB)JSX=@TO6O)74)%01M(-*A99J8F8W5A(3).A930C
M*IK4<HY5YG5S2"T+/94=HHDJNBBCC3KZ**212BK<=IRP.2 D[-S4'C-6[<(F
M7;MHLM6GW>R2(J#=6*():F\:5*$H7.TR3J'=L*F,5YK0F%Z+,VK"S%61*4@*
M5!NB=HXE*_V697I#D>?=59CI^1,[K"AF4$4YG:-:5.<=:!Z22&GJF"SC=*/:
MFJ_:^FDDK6G#R3G*-,4+3'HN11$[Q%R&U4TB'B3,EJR(TAW^),(T.PXGAY3G
M)#'^XLO?57(A=$U3._[7#6KGI6>OGO#-R,DU[XZG25608#8IRBFKO#+++;O\
MLG+1P'8R.ZA$AILHJ D3R<-:?1>9O*3L)TLDHC E(B?=&=308\3XQ$N<RF"K
MR35OR<)>;^Q<XY<VI%C"233=<!*),+1:XG32WD$=361;,6/)M_F*<AG197/2
M$"^G[530MC)O>Y2?++$J<XO7F,V7)HE[1XHHR9Z#")LTPCW.4>%EC2 JENX<
M&4HGU4P,(@9>\[5^;6_+*SO=*./Y97:-TQM+REABR36]_<23SE=1**6)D=3"
M2T1;4\W*0DAM"3/RR2N_///-PTS^LY._&G2.=U-"+QQ]OU'^&_77 Z<-Y=5/
M:=#VPHU#5O?35W^I^-Z?#]S[J6.+6?:1+W7]D=9/'US^YT/_/C$<!+^3T<=]
MWBE?<)A!,O)M[V3CX QPZ(><;H@O.-3K35(R4BX+DL4[N%F8\T(HPA&2L(0F
M# XO_G3"%39G' U)5#=L1!PF><\ZM=#/;Z[!'N/\B(4^_"$0@RC$(1+1.;8J
M(A*3J,0E,K&)PM$&"%U3P^:=8X=3LN)SH @< 3$G*_>97GR"<XTI*NJ(P,'B
M<LSHQ#6RL8UN3-0YM!&-<T2%'=%8"6X*(D?,0/%\VF!&0?KS1_QA*W4Y&1\"
M4Z>,<6C^0RGC"%MPQ@%(K;%GCT[:SSF8P99QZ% ])OO-+HQB2 L:3G7>849Y
M"&<N])WC2);,I#:@=YB"6$),OV'&'PK2P6X08C\=O"(C@06_:PA3B]W(R2+'
M097[_2:&#]Q2- 2$2SUB<H^0S*0N(2DD159P2LS05EZ<Q!9B4"]_9'PC.M.I
M3A)VBA/P8866PL.+0VA2% UYF[$8IR2>"$QJP!$&QAX#'[O53(8V\0K ,#(J
M>G$O<X5AA9E4I2,7GJ<6G/')15&!"!!J(@VV&N@6R0:PK=Q00W]!TWNV=8V<
M6>(ARO2:#%D"G_I\T35? "1J-#2&/]V'*J@(BSUEJ!ZX,0/^G]T8F##D)0M6
MP,MIO[FA+ A!"%J)0AFUN&F*_J*-2+C3G8>Y"YRZ<@U"_*$J7A%.G_C"BU\M
M2#]6:LJ!&+K.N=*UKLD[#5?44SM-3'5+1!,%(0#&#ML<]0[=X"<Y@Z-4]+"%
M50["H4$T<<@$6:(JM))2S7Q3KG-<#2/Z2=8X_B * F7)*S6ET98D"Z3?V*86
M?R#%:UEA$$@DSG>U0 4QE%3++?TG7_XT2-<,ZT7M1<))%JH*!=/#"YMH"1*
MK=X+>PNV]DQ&5W!1449VP=D9&2Q6#M*$<_\@KVJ-@SMY@*E<0*(GBWBO7-WP
MTXPJ"Y-N0 (5Y\C9\>RJW_WRUU'^H3F*IGXJC$.,XSZ,^R9X[(@49A!"5<F-
M#,W&02#J5@LHG/H-*73)"F4TN$>8;<I2WE25MPR6>K+8A2A"@K"BWB2_J%U1
M>50K&=ZH)!K;,0@K:@'(T-BD2;U%2'H@]!L9,5A5ML16<?W%"T!1+B+ZN0G4
MBOK/\O16M0VQQ):$ 8G63,]:6-&&+ 13D17I)VRM>J1H$ ,325Y#3YR-C/@@
M8:N=_,EHV=JF8$[;WSWSN<_.48;4I":,C[#B$"UB)$(0TR1M$",W>2BOC$AQ
M6^RVI[CZ$L:,L)*'0]K1+6Q#SSG@U4,GG><D=XG1?4IBT=!TA&+1H%C7OL<*
MDYPX;I3^##5:(*.: #9L%TL^!%LX01/S:(,5Z*EIL7?QZ.&2+SWE%08K."LU
M9J#')]%H$#%0P]K:Z/A R@C+=@0B(%=-;T<WJ855>7$9XMD$+7]43Q71A.DV
MQ_&//&F*3+C<GH\(0UR#E@7 $R-'0IS3SP8_.,*U!S[],7(IU8MCY(ZHC"BF
M27W3"V<$8VDN\CD\. M78S/9=$3TD<5^^J-><<PX\O+4CWPH/Y_,G,H]C)NO
MF38?'\.C6+.28 9:OSR?V"+))LHMO.-.ZB;Y3&Z]A:\'.*=B.0%+;KWQ)KSJ
M5K^Z=3Q2<#:>XRU"=50LD_,[E%U/N\@YB<ZQKO:UZ[>*S2G^NO/06!W#I3V"
MU<G><AH>J59NW#A;9SO@ []G535G4]-!"71B>)S^#">1P\DD<79KG#I*AXZ7
M.\XB$V0<Q-]2Z<5Q/#$@\89(R'W(=1<\ZE//1F;P1!E7B]=^,%U<V] LA;:Z
MW&14,F20T#$K4\J:VV/)-JDU?2F(&>Q]E$DDHACD-!,:AS)F-63$4T3K3D(W
M(:)]?-ZTLC=\3%U27)\3(+-\80N'8A5E\=OK<UJ9 #W547CB)$ #)]O&M]$X
M\M 0LI%%1IP>[#78!P7I7[[,"NS9QR$1 [W,#OX4UU)4W&],!OCTQ%F<#S$(
M0X251RKYFNIUH >2T"Y PGH W*G^Q(=NU$(M^<D.01LIA!(K+)>DC01KB08O
M$ +CW%&9\ +A555HD-[$(<B)N,@+BDA:L$)+\00=;$='M(L_N9 L?):Z^5I*
MH-LAS-JO[,5'1!4KR,)1 ,J&.89NB0EI?)-!T,2V -1):,+"'-5[+(P+<@(K
MD(V+*(EJR!!-W$VG'%+^/40M"<.[R )>_ 8QK!0KH,(UY,%#T :Q6$(T$(*0
MP ;43(0E-."#\(+Z_0; >40AU@(A4 8<UI3/+)D-ON 'EJ(I(@]YE*$E( +K
ME5A5G(1O/$A+^8V99(P,'96$5!96G,9@C9E^(,P;? 9[:-X?0$*[V!\G&)9Y
M"(.#M!G^K4B?UA"")OS!6L6A);"&C1"#27 76<B+7/2'6_@&,^I60MG,R:@*
M9:Q'-&A"*M+(&U (>IS''#6)-BH#))15F&E;5=R+P0"'@J@)V;P!>,F0CLF6
M-MX$*R#"-:('Q.P((1@C//T?^3@(QOS>;T#;87$"1D"(_=5416X%13#%*8XD
M2:*,L-F1&IY;S6C#-9A,17S19RP(\)R#L45$LOP&V(C"\X4&7L5*<9V-6JA$
MH33?ENB(K2B@>1 ".3U$<;79E,P-<"%"R,S%5H"9;%7+J\V(6[ $*GSC.!@;
M@\C"5L%$G>2!KOQ&0A*96,J8-D@E^% .[36)B_ ",R#"5]K^WU*@@DF<C8N%
MR(C4Y50^E4-4RTJQC2CT!*ZTR8YHX[GH6>H4UU&]#I>9RDY(6LV@6]GD%V[<
MEU3DQ566)&B&9J(89J/1!B?12"U PME  CP!5YD$1D3DQ!8"VT4"%M2<84]P
MQ&!90B_I)+ 9CF1$AF-H9#2T"V4(#+T<"$OPPI;%HHN0AB$FSL3]A3((A-L5
MI^]XWV7,$6V\1YRXD.NQPR%0FF 9CK6<""A-R,+TFQWU2G@XR+5%C@*YA>=<
MI-"T#:VH9PX=4XO<D1^* D2QSAG^H6I@EO9\"]$P(EIF9[\5VF,<2=QT'2G(
MUFN1AFA>*(9:!\EQ$,?!3S>ESP#^$8<#T0_>$4<W+M/^1!"(<H_X5$\#11"T
MF,^*(IGG38_WH%QQE&C-B2CV()W=Z8\%&5W!)1*.0A^N_-;UG$PDA%V&-JF3
MLE$G-4]U8EW7F4ER)-:39JF6$L<8*8>/4H?)?2ESB*F(8M$O+8>./L_?+4^-
M;JF;9FDWL *9DL]91M+I+0<&#EG92*1S+%ES3$9P= <T'@=;?$5Q1*D%W6G2
MV=&<"H?0O!USM!)V-)S2O*FE;FD/L0<GK8_A["-_7E$(8L81+1PCB4_(? ^]
M,:K/A%W)C5$5#1WTQ-$<29%)\!%;O*K61-%#8 M9O$EW-%PBL<DU',(QG=45
M15C)Z=+^& VFUKP<_=C8?>0/DRY<O363-IU*#J4/Y5Q#Y-P7FS ID(H3C5RE
M%FF/_BB+072I(56/EE6%4J1.Z5VJO)IBXJQ(YAS51G69;FS5H)U';MU0'I@$
MJ^AD=R2.2\&&L)V2>^2!C @,M8V.=MU$5WZ$>/U)I4K&'71E@PA#)DZ&F5A4
M4G1E36F&IK""8[W.'\(%3UQA:Q!#,%9$;3B&E4K$;?B)P9R8+/Q!BY!&>NS&
M;1&-KN#63BPI>E#&;6W%TKR'JA#*;0 H;CE-1RP5_@4CH)@(UJ":B="9SFK%
MV$U)T.Y%6+#DJF&,B1C:@]R!-OP!5YW+;?'IO+ZM!Q)#=6+^!"_TTRUMF&-Q
M@FVX!ULD9E$E!(V\!V(<YBZT#DY*34/$QX0B!APZ!G>XGLU4&.HTGZX(Q(08
MFUS$!HR 3&VLU5-Q:[2=Q)O0Q'Z@ E,ID+[H8W$9ZN7&QE-1AH PU:PYY9+M
M(TL5A/T!*$9<H--<PT=@*[8H4+M5"UP,5BULV&W%1I/@6";M[A?U!>N5RU<"
M:N>>I>T*A7;=T9)EFWLYX'>,R3A 2(4,&MR6;RE^T[#5K>&EAJ5 44P TE'E
MA.8!#^#6K=!HR4HMT++LQZF(92/!TUV8AL$<B9 59RPBR);\+8 >"5;T(Y,@
M1-^E1D\8C990A)!$1%/ 89M5%I+^V5&3B(GT8B)(W =&<*RA'N8.,B-92-G<
M1 :FP=.Y. DDW"II"-1^B,E]-,7LC$?81(YV-5IJ<%F[%!A]+)>3 93(%1<.
M64N_Q8KVFDN@?*]B"EO^F*\5I]Z/W-"2OM#T?(U"Z =RAEY'D,<=(<O=<(3,
MZ*5JC(IWR,@TEI? 9%LT&-L?T,?7]!M&7(-1L,1OV"-8W4315->$HN!.0(+>
M_L9N:(HF!(6EZ&"?. BNW)>VW0L@1415<94,2>%*#,RJC ZJC"LCF@@J"(.2
M_$3B0 *CR5&.10(J9X0HY %ND()&EH:.5$MQ_=5OM2"@<$(K&X2ZI8;I A1Y
MV.,A/TC^,LK.>135DMD&>)!"I@#7DHI:WA"(HEZQ-2?<LYXI<%S;^,20J (+
M^&0/'?4<??P2,7W/)-G1')4SCL(2RC$DV]S2K^B2-Q6$)IF+,#F3]IP,)$E=
M)M%/!T'/$?7<4J0S,XDJ,?&1_R"(^<W1)M%''9&H/F/+#W*2,#T2.0.7,%T<
M@K3/R9SJT:7.1B]%V-"1MJ!<]ES@\@+7^]0/%UTS3,>T=(P.GV:(3 O'Z-C7
M3>]T3*_I$ODT3P>U4+],N5I<=H2O<5R>I+A=#G43VYQFXT6U[_I040^U5<.M
M*CU(:\3/ALX/H$Y/%9>/N9S6]2P5]YA3L)*HT5E/.^M2GH;^=2O>G%B3&-]0
MCJ0VB*B>S%8Y2=F =15I&P%UJ'!0$ .9J_Q,";0 E,NQ*)"^7%?W7(L2$ %5
M<?^0'#LCMO8<$$!K#;RFZ%5_-CKUFR402#?DP:.M%-@@ EXL\GV@(#/>P28U
MSGVP\F5T@S-[KPMU761 5"3HI0OMQ'UMV?1P@E^L!MT4#5/H;9R<!2=8PE*A
M@=,,S%>LXF<6SA/*Q<X00F4MTB+3A.^P A9D&Y:5!W@/XA_4DGH4C270 5N@
M4IR*#=E4I%I\QZI T=@0&%-13++ B8(2 QI$!BE$@B;PC3WQPGCW!=CT"6\<
M;XL #,B4(<\(\XP\$-FTB&D(!2?^^,1.Q.$+.A=9H(?OU.!TD@U(Q(G,Z!MH
MI[@3A09Y;,A_L<;LF RJL$HG6@*U(,AM/0Z8W1 C/3.(V-B)Z*3%:H1HT-MT
MC1EZF(R>G$=E[0)?;-G'J#",LZ/E^6."?!,$#?"&J(A6$*M5Z.37/"9]7X63
MY*Q@I4YOY)ALH4(&X8LRC?*&/(ZIE!<BU (BT(' /+,@S8A,W$@W_(' 6!1;
M1,)YAH9^-+=S$YA>M5F*1.#/J@AEN :A\%6=Q8JTS$B!-$F&%R><O. 6.J:*
MASH2:>]W?,:?Y %'-B5&K >=R0?Y="6\Z"(*4@ZE)0;C",U_Q81%Z"!WE8>G
MHJ"FH,;^1\AZO<S((-(+JI]%,U+:01:5)F!$@F0(NF@)P%7$?4$(6Q >HQ4.
MC"A$+/Z%;0]-6*A'-Q:BKU$99,3+L^^"#:*;1- (:O!&6PS*B0$%9JBVCLF,
MJ'@$9RQ9M+B&C;VZ19W'C4C$KA?8#\N%:T3&6_Q)H%"-S51%M(DZQ2L1]V[+
M!:8'XU0G?.[V>VT8,^K1[]BE+GX$FPO;57;(!4Z5FWRE"3>)[XV#A(2$@]0E
M3:P95LS%'\ .%[Z(W"K&J+R+1#"7B&0PU5 &),B+WAJ-5S!$4BV%5TSU3Y -
M[6"6,!""D^0&)&B)@6-&;]@3G@@#06P%?:';A/"B:^1%P>C^'A^W%I. #0J>
MAMQ>PQ_(#"3DC5TPA$*XR\@KPU38-K'$*::%!2+4!B+DA)FC!4;(LFUP!D^P
M<L5'?A'9BKKF2S>6A!7=:L6]:^T41+871$C@AF_0T?YLW":A?4AW R+ 7R5Q
MT>=?W]E@1I>JF21)3:-K#2?1!_@TS XU$F^08</!Q@'%T@X!FD.#TK<HDQY!
M!?G07]>!SOI@*TE\:T'$D,[%$4,A!AUIX\9]M Y&X*R>D38R3"J14[S(+1[)
M'&"0TT!/W-_$$MY+OOQ?715#!Q_CZ0$SCU:X+7%8%4@H$4 ($\:.8$&#!)7)
M&G>084.'#R%&E#B18D6+%S%FU+C^D6-'CQ]!AA0YDF1)DR<GGCMW425*EQU;
MOI0YDV9-FS=QYM09<F5#;3W9:>/U\-JUC3\;%E4&E& WI@3'D3):\.E.JU>Q
M9M6ZE6M7KU]+GAOH$R@S40^9,6NH3)M$IPW3"GNJ;>%!99H.1HO&L2I8OW\!
M!Q8\F'!AA]U(\8HF2Y904M&8T3D7C1.Q<[QJ";U;ZQJSRJS&=N/$ZS*OA++8
M$2/%BI"H<ZA$+99%C-TNJ>R$7=MEZ9HV4KM*DV(V61G!G[9WU67UYEJM<VDU
MX>6E39NPW=>(R:J%<#BO<;:9"4-%ZMPN5-%JH>IKF'U[]^_AQR\L2U2W6MT@
MY18&:5S^K7&(B*E%&5YHBX09W83Q3+BVV(ED%UX4J\62NV2)9"]-:#N$&5)D
MN0:2: ZI[AQ1:M&D+6VBT:06R(01;I>I1&%&DUV$804AO"(YIY9:F"DNQ@TY
MX6S"T=A11A356&&%&$24B082&7?9A;/UY*O2RBNQS%++BH09:BC0DB3DLF[H
M,*\;8KII\!I>1!$F&E&NX60L0E!AI:@*M9.%$X)8V<L2Q!:211E24NM&%%GV
MPJV60SB+AIAH>+&DIPY_W),=S]BQI+\7]^(D+5*$8P825A!EYQQ+SA-%E%UD
M$486WF(\1Q;RMJS5UEMQS14PR$8LDA51E(EDG/IJV469:TK^M4088E@1;K1:
M$"'(U;1XV2427JYY+3=EBA-6F-$XN8P=.X]DA1EM+"$&E5V(X864<2S9CB T
M8S,+H;-6_"T[=G8D11/A&L2V(%0(2<V2 X$EQ= >A=&P+ETACECBB2D^JBW:
M>JN3-F&*HT\;9M)4!C%4E!EG4%08Q(V3:*Z)1AM44!L'YFZ&HJV\V_8J&>1K
M$GLSLY:7TB11=JX9!V2CFU*+'>V*]H_?4!>Z!N:"%I,V1F%(?.[,RB:KV.NO
MP0Y;;+]8D?2D0=,<6^VUV6[;;9FB2=ND;J9ZV^Z[\<Y;[[WY[MOOOP$/7/#!
M"2_<\,,13USQQ1EOW/''(8]<\LG^*:_<\LLQSUSSS3GOW///00]=]-%)+]WT
MT_76L2T=G=J%E;9X@9F5:NM,6QE62.ZF5&V<2RU);;H!+K7B[%.H2.?*T\8\
M5N0^2'FF7$^SO[:F/X@95L;IID^"F-GEH/*VRZZN7=32_G74T4]?XG..0&/<
M&)@AY(@QIB"&$RTT2 .2&K1(HSAV_J"",?Q@%VCXPCCN(!EV?$$(7SC"'2J@
M%BW\01M'^,(4OL",+YS@/#\@!?_>\+^#R"('*E!:IK#PA31TXP]"&,,X_O"#
M%1:$$VFX WZ.<(1=: ,-1[ 15,9 !T(0XPM-N,,Y-)&$(UR#%6D0PA2HI#XI
M3A$^D3C^PCD.\099-,$R>7A#D7(0C7$(019 (00:M-&$5>4@$EA(5!H(T8T8
M).$$EAD#(2R1A&MT8PJ$>(,*DD",'XC"A^LA11K"6) TT($58]A%#6J!!41,
MH19".(NIM( (R B!%5H@1"3^L LLU$4939"+)L; #"SLPI)I$-:IA- \*LZ2
MENQA1@U(T819)8$@D, "OXY MQHT 0VT80<BDY"&E:3!!98HR!^.0 @A_,$%
M3=!"#M[P!2T0) UO((06C'@"2^0@"<4DR#F:5)!*=L-D*,H!&V7Q T$>007$
M: (D.J.,'!SA!X=H AUB\(8_I*$6/XC&L2*1 SJ,P1)"R(/^"E#Q UF,89N'
M4 $D:IE1C0[F'%H00A*TP8DELH,04\"-"^(6 TV\A1UTF (ODF"C6M2S(%](
M B1N5X$738$.?YC".-B7S3MP8@0C$$4-.,%284P!$3WA!4IK\05$_&$,D1 "
M*>K9A#?\0!@Y@,0?T$ *#8@B#6CPS!$@<8<[\(*,6("$)6H@#!7$3A-->"HJ
MT) '=HPC#[S<Z%\!VQ52(*!@U_@"%O+ R=34(&XY2(,E$D6('.0A!JA11@U.
M^(4_\$D#:M%L-VJ !CIP=0Q_&$<21D *&4*V( \K$OQ,!< [3N$:94W#. CQ
MA2]D2R58> ,69,&+2&B!&,K0@A;^(K%7L0CP")[)PQ_.<48LZ"823<!"% .;
M7>VZQ#?_LP\I_M>?E=0"5%,9%(F@(B^$_$]J(2O.A@#&+:*=A[RW:4A_#*(C
M4K1%=T;IKT%XAPJ3 8P=[G)MBY@A,^^82D!%*N]V(1QA"4^8PA6V\(4QG.&#
M=..$(K&,0SZL%=?FY!PCSH@L40+4$&N8Q5?I$=&&XA$=3013!L&O1:9S$%&8
MF"#"PDA1'")?C9RC:!T&28XG,HZZY5>]#_G?T,ZF%C%>LL55ULF.BE2?:IWC
M92?\#G!HEAF7I:8@S'A#]@24/;58IAO"$- A4%808H00-P)SUT#&X>:Z:.,.
MJ(D&C7#^,PY9@+E& T%$@\LCC+:05RU"\1Y4.*$))0/ZG)HX1(EK$:#,I&;!
MV=&&,E#!HP1UXW:12-E"=$8*VH#,5+IC$(KV>BG.7*//J1'*IIE1BP[9N#_E
MJY8LZ+!'Q0!YU;5@!2)(\]X5.7@[O LQAU/#Y58]#-J6:=<I#S$.R\38RMVV
MB7R%@IECL<L2#.I,>K01(\4HQE+L0(R."&2L/95;4-=0QA_L!U2ZQ3$:YFH,
M(7:1, B-Y1SY"2DS&L.+9@WH&G "%B'$HXSL()S/]J-,@$X8)29&XSP#.XN4
M>C2KA1'#-^?ZEX28<0AB (L5/1D')_KC(6)$0AF*UL:CH-O^E/N(HLL"BL1
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MFKB&8J$UOE$AHCY9LD3?:B(+EL +%6&9B":PQ0E"N 01)LDME5"AC*")46<
MQ%>/X!5'=OP!$=-1RSFNRJK+Y2=/D4F+2431K)(XBTR1N"FC\ K@  O80G^P
MZH'. AI>B%89D!!%;3,5DD?]EQ.00$2R#*()3NANA82P:E%(VYM:<.(/T0A.
M7?Z0K(-HIV/8:A=%ON=<]Q5F(D="L89#$K"12<2Y?&+&JNZ 5+2$!!7,T 8O
MH"48!!?^A%&K*DB^3'>-A<E($^)ZL8]9VF G$805S'!(S;HE' 72@1.<( :K
M^"5:N"'Y13%:F$3.9!.[N=BKD7E+1#W5#59DEQ@^4FS<V"$*S@DP;A%Y$9#Q
M-.!$*WK14?E4-QK39<-$XP^^B\05KZ$8$0E6$S72JSM9AHH[X!%,L6D4:<<E
M"VU (AJ[R(,V\DS1M;TE4E.RTJK$ @G0#'-QPB!$D^PRIQ/=2%^:FU&/+[/,
M>>8'0/,)6+W&<29VT(L4*5.,JJ-QUB$J)SVK @]^.Z:,:VP'IS4)210[%-2(
M:/B*; $OH6X5L$"9*G8*)4BFYF@>31QH89%XDN;NBZP"BD;^4,-TCTG*7-NR
MW"H:KDXV;MW,Z(A+/.(F-/-%')*@EH6SB N7=DO>QY:"1,,EW7#(=7S+0U,*
MAF<"V<ZMR"V9!SY:(O6*R*DP0AG-E6M\9U':$R48LH3B2(*04:G )C)!DCCJ
MB*ID*<#,8A'+8:0U$>G.H$.F$CG!KS44F=7E_ *W(@MCK *9^5>B08PCYWF(
M\QDIUPO2]I\DZ#2F#+>:8#FB@<QS)@ <]!^.J#GJ4&WBA"^\X5-"9 VM^/!0
M$1IYU+3-#&UDIXROO.4MOY++HV\<S O6=2*O^="+WI"1TC!&I*Z2>$GU*5U]
MY4#$")VD?$;U6$$F0IRNC9+ #SS^<(?)G#Q%9IJX\C-:'KWQCX_\K1&C+Q%1
MCR-%TZDQ800F#2'@0*H__2.IB22.S%Z[P"/&(*8DM/.<?B#;B!&3#\4@"W%D
M?1/B8%.R!3S/)0@QWJ"771.D7G3]R_Z547S))X #2( :(F(1<0YPXTC,0 @A
M41T.>#,'$QN<T%_=0&;BI@F10 >/QFDV,C?R4B^:0!G%Q0K.52^3 DE&@Q&R
M  ET,!&D  E[0PJ64!PYT@VL00R1<"WI$0F2XE3;AA!()0P1,X075$N")1',
M$"_CX#&S,2X%PGL%*(532(56@5%8(B\+01L+(@IYL6$D&$;RTH4'%3*(0 R(
M4 N9(BK^:],F2^-9O>$_)F(;T58@FA!.B1<T5))G"C,FX?4'\]$-L>0_$1-%
MY1(Q>\%J8Z<FAR!._E)+W$,;!$1,Q5&%E6B)EZ@4%J@R,F,;=0$RX),=!20=
M;;$+WR,,3?8BHZ$V<U0N7K4DLK!MHK5JK  )$*<-/N&(RQ$S)6$OVF(CU^50
M3"@0&:87JF6(5*,=I=@6,9,0G- H)580D",1W6)!V82)UXB-!3@9:4$0Y&8N
MUV"&T2,7FS-7 ),DU\ ,D& 672$,=Q"(M=$L8E,0V25 AX VS_1I8Y!['](R
M\D$6@98'!<0*NT (XW!0!Q0B['!0TD$*8K,HNA,EQA$7_ C^:'H!& P#2159
M2VV!+T.T-YS!)^*4C2-)DIHW,RF3$S5$0$!D<9U"4>8190X!,B[1(%(E10AQ
M<P(T$'-B'L$C0*F#&4=6=^8Q/L( 'MUPD]?P/@<A(#M90MTH#,K$'0/Q:@52
M$:-D1 .4@"<ADB7IE5\)EE&!:31IC6Y1)%T9EFFIEFNY1MC'%)G'EG$IEW-)
MEW5IEW>)EWFIEWO)EWWIEW\)F($IF(-)F(5IF(>)F(FIF(O)F(WIF(\)F9$I
MF9-)F95IF9>)F9FIF9O)F9WIF9\)FJ$IFJ-)FJ5IFJ>)FJFIFJO)FJWIFJ\)
MF[$IF[-)F[5IF[>)F[FIF[O)F[W^Z9N_"9S!*9S#29S%:9S'B9S)J9S+R9S-
MZ9S/"9W1*9W329W5:9W7B9W9J9W;R9W=Z9W?"9[A*9[C29[E:9[GB9[IJ9[K
MR9[MZ9[O"9_Q*9_S29_U:9_WB9_YJ9_[R9_]Z9__": !*J #2J %:J 'BJ )
MJJ +RJ -ZJ /"J$1*J$32J$5:J$7BJ$9JJ$;RJ$=ZJ$?"J(A*J(C2J(E:J(G
MBJ(IJJ(KRJ(MZJ(O"J,Q*J,S2J,U:J,WBJ,YJJ,[RJ,]ZJ,_"J1!*J1#2J1%
M:J1'BJ1)JJ1+RJ1-ZJ1/"J51*J532J55:J57BJ59JJ5;RJ5=ZJ5?"J9A*J9C
M2J9E:J;^9XJF::JF:\JF;>JF;PJG<2JG<TJG=6JG=XJG>:JG>\JG?>JG?PJH
M@2JH@TJHA6JHAXJHB:JHB\JHC>JHCPJID2JIDTJIE6JIEXJIF:JIF\JIG>JI
MGPJJH2JJHTJJI6JJIXJJJ:JJJ\JJK>JJKPJKL2JKLTJKM6JKMXJKN:JKN^J;
MK5%D4\<D.7ES5G<=2D@_2IB2[8<C!X&.+X01 T11%)$1 H,CR%I]-S=R,*$T
MVY&M;LD:Z5<@)%$9V.=(+[,=;)AU'3=$7;9_6&<0C?$3!N%^UCH0.?E"U[<2
M]0I)LC%R(M0:&.>N:Y."$9%YK"01)E1^E6H9B1&5E".-;D+^$%'T*&F&"G0@
M'P1I(GN17OTF$=2&$1D6-#2!'041'*\3/1CT*G$1/**0) (B-""#"F*E,MSU
M:E8U3RL"%U$47^= "%\Q5@1Q9)#0$TM&LQDG,A)S#HC@7/HS+ZD&(E%4$ 09
M2R<[4,BQLBT+0(K(#JL"3(WQ%OW",J<X$%.B5RWC4=U1(FGQ)!(1)[=("HRR
M;,1 " )A%C';>9.Z8A?%-IUQ#OGB1SY6(/?E$K$5M7?0&;R !GKA*ASA1S6A
M%LP@2Z^301%#>8HE*EIB&S(&2?2B#-U62UV4)<2@&N0""1!S$/@E'XT;L8TQ
M'.7R2<MA";)10#M)9*"R-B!A@8?^2$\4<;D$,1AGL61/4CENDBS48K.*<A@D
MER^<(58<84]@T2G4E1L4& U1%KO[)TV2ZHC,R!F-XB_%(2 J@1[.R(,XY"W?
MTS&0H!?\$KLLL0LBD@>=APJ0<"01\U\ <UT( 8MK@RTIHPE_P"FH<4!&<XCD
M(G;Y84P_0A8UPCV6\ =Q03'/&S/*H4$JV#N1%86R< ?R<8C;$A>MZ"G:-X]*
M.(2-40MI0$V/\JVLAGHB5A:I\R+.VRTB/'*406WUX2 RF[V2BE =,T6=PF=C
M=RNUU!O_M3KF.U!I"".,$EI?XA+*$C3@12W:$4X1XT.FA"4+,2/NFB?;@25[
M)<!CH5/^O-<@%O@S=K@PX<0SJ #"9<8,4XL1O!<TRM$IK&(0#U0D(%P+?3$[
M12%::=@F6IP6"\$H"&(3UALTWO(TIB(18=*-Y-$?!A'#:@()##-%,]$7K&(7
M#H.6D/I ((E;5*82"]FW+,6-N<A[WUIN@\4+C#)V[V2!%G2+!Z-*5S56P(11
MVH O*B0>N2<@.6A"@A>Q#A(JGWLY:7%>YY 'I8,X2]8LZ5')$:L,8&PY[S4K
M1D(M,B)DI((6WG(E76LP%JA"RY%[C9&#2[8K\Q0^GI@_T/9J0@P=9](:!'$?
MAL(,5*9J*Z$6H2PQ*+RU<$@=B4*IGRPQ=DA-U5L@:=6**S;^6"+""@4%,N-!
M+G##K)S!&6DG& 55T'HA*)?!9P8D$7RF-O/,"C,".&N3AFIS#LG"4DC%,Z)0
MT@,!TGFV$+YC<_&"+=-A@?@55K65'F4V1/9Q0.-@'CQC?RW2T4S3,F<ATM"A
M%T\#M+H\$ @RS\K MYV2(*(K4 #3**@1)I?S'9PSD 7M6RSA$&51$P^]PZ\*
MO+SJUF\-UW$MUX69-EA7E6K"KOL7TN41$PPQS6,Q&2&D-B('$=**=FL]UY?(
M"HMS.<<Q&YX52+SP!A84:".B6I%S,[SV*C-A-@,AV2]DAH F&?^21A?!1)ST
M:/GWLQ@!,D7&AM5W'4\I03#Q,FO^4R]XS76VK4&9EQ&Q7:]M?8(K&:X2='WX
MVKTR@4.^C=NIYWO F]HB9W=\>K^1,F3%8XC/04[CDSKFTC'Q\R%J$50[=@@4
M(3NWDC^%%(H:4[HKO=ZB0+.SP;)8$B=4 ADQF[%6P@FFTA_Z!&T2JPEIX"]'
MI0F*M=(F0;48.S/SDCUS!+42 QIXA!89IC9OP1DB\@>)UR=<E#8(TQTQNR1F
MP@FK,@Z$$.* EFMJ(PP9=DYYZB&!1(3$X1>$P7EAHA<S\ZSH2 >)!S8$ 0E8
MT"I',B>V40N'8)2@QSZR4R. UA8R*VVMD3K1)<$%I$(?<7(+PAE.4BX+8C=&
MME>^"X#^D%! 'Q82HGCE< ,6!\$SVD'1IF1:-<XTH'&]XF)!"#5!K_-;%.%'
MMZ@H_Z75G6RGVH(VZ:%3G3$C(AB_1"Q 8^Z)JP:T--$A[%B+?R@<'L4NK:5'
M)ZQ!R:(7FM 2*[W8(!S.M4@,>= C*,/7#%,;+4;/#/8::H(>7;%,+8-4< $2
MGC(WK1R-# 9U*E'B!5S27Q%EV';97B5B<T(>,Z)MWD(H, ([$S07 UF6=3K@
M&A0QX'MDDQ&_UZ%@ +/=.395W6A:>4$W?XA>?9$]&'WI(>(0,+WIG<[N>P'6
MDQ$U) $E27P=<4(=CE6V=O,RD&M_14(WYE.^0()!)U*V\^C^$N][A-7.*![%
M,I'PT#PU'W&R8P>!)8?@-_]E(XU\MW=*#)S&/RX92/;70<D"L#C9U?'BPOH#
M$1$!(RN>1OX!N$ M;2MROU$K8UZ%E&,QCO*R-MH,$C/1S?8T$_BBRV+!*-I
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MC8$&#C$.:&OAO='XP;M =),<=&!P&LKT#YSR!Q6,@PY)*"7>-' $9DQA"NS
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MY!OD)Z^ E28$$B)=FBKTFE1^LU@>"T0.FUF.FEL6&L\I9;! A!&( ?>TFDB
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M)V92IK<IT+8DN -*/ )EZ  LZ !1[P!"D+@\H"Y.P )?RXO2.X\<> .8)#_
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M'*B\-T#WPE(&@R/Q<_B#$1B!P-)+B_N",?@!4<@!2]@_@(C&;B#!*7_8[=)
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M?*L;LF!)V(3Q.X+P@I,PI$QK+'$(47!BIDX)IV?,I(EB#LA_K<'J0+3!"UE
M0AB[^-*!QM:-.Y!BA 39Q9]"@@I+_($494,H8S?""@3D * "BT0'.H"]T41#
M%E-2QB[^L+75$<-3GQ6--NX@-8)<@PZ0B LSAJ*O;L!1-*/5WCD0H;>!S9:8
MNY#%!J?D*V;<2I((2P(A4)&&)"!"0$?XDVFN<01(H((.21 "),: %]/(0@5I
MNL8;_E#^1T3P1Q/(/80RIH"&0PA!&%AX#&:C81)F_(D8M< +3*)!BK70MX7$
MB-1-C?J<6BB#2B&C)SMNRHE;UBXGS"!$W#C2E;3DY!IE:=>4U(2*QA#C<B5\
MSF&-E!A60 IN/CRE9]0DRQ+*9#.*F1<I4,&,^S:F*C,=QR&\^JTA9B2T-\UM
M8_6IB1&<X+0!.P0#$"!&TXA""Q$X@EF/P&-FG" )&!*N9ZZA.<^D00O..\<1
MIO %%62$%\K!F^*R.(X:'#E@RDB#ZJX1@S&@01G$^,(7A$ <=B1A"F.@7&F(
M<<ZJT"$22,S#Y4C#BZ'J) ]OD 4B9M?G+W275'_5W2'24!3^-,Q%RN!!R!W,
MQI$,AU)%9:')@<9$0Z:@(I7JS!0I>9%A6[*"F\[:4JFO08JA0"(:?Y(=,4CQ
MMPP/1!2:@(1?A6(>3O42F4)Y:RV$P0I[YC+ (([&(6J1:O-UQ)O-7N!>>2$*
M1 \DUN> !%R"LHO,<DH3NY"HKD.)D&@,Q=<]=M XWA(->^/[=_F^M[[[S>][
M"QDTFD! %YM&B"(7U#3,B$!."'$$GR8F&I"(1(X6S@I>N  NWU[).""1!U)<
MZPV1. 0K"*$)C& L$HD-BPJ$P)UQY  LD#C"E&J""$B,4Q9YT)LV$/$&1-0@
M!C4A!B+N@*<\(((0"VDG6?YP"&+^, ,22'04'?!2BSOH;A?RS$-86Z)UY/ "
M$I90%-&1UXT_0"+.><)Y!\[I](CE(2>'N# DWE"+&R)B)I!(##'>,* [7*/C
M>?"D%CIP"+!I@E<0=$$RFS &:MWA0SE(-</G71HL)-QM[9*6WPI&K1N&*R[G
M@ O:C-0-]X()52<;6;4"#[.P\.QN*4P9E4L2#7,]IU%HTTEDP%2TSDBK8@Y+
MX;,ZOZC/LX.7JP=9\E=H>=.D\00=4,$(1N""Z4O?!=57P?2YKWWK=^ $TJ>^
M]540<,^@H@ UD&S (%'9]YV&I7HC10TX@?EST$$325)4-'* !BUH03PE@7&]
M 2\@@B;^' &DU  B>!<DW($+X,DY_!\K8 $B1,/_,=<7U 1ZH (I$,</<)TE
M; @6R$)^Z$H2) %[) $G'$+D-,$;<,(;-(']#$0>#. N1,<=F)R(]%H.:,(A
M: $=Y  G-,$7B(+G0$+]38$6'*$H7 ,:H,(A( (OQ$#::4$WI(%_%%(>I $J
M.,\X3,$Y'4$M*!HJ&,0U/%0ML 9"N( L<,(53J 6Y,$=-$$)[08BH$%<:,,1
MW,$4TMQ \$(24 @:W(&2/-]HG([ Q(30))/MU-5YC(N7:(3K/4CMA1 $.=]G
M2$NAD0PQW T&2=2BL-\A+HW[5=\I<A$J5E\JKF(KGB(JKI_^:7""]9V?L" "
M S! F95&-*B WEB"$'3'C%3 %XQ!!P0%E&5(#!!#$H@1*8S 7=#!"5!<&^Z"
M"PR("_R)E>7$']3 .;P!&I3$<YV'B&B"$#!##(1$$[S@F\7 ;7V!%K##(<1
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M<\;J<W5#<E3;,DI&$W3<%Q"""SQ3T37).'S!"/Q)),CI>DC@%]S!#^@++]3
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M!9PXA604V._<5VN@ B'$6E^8KJW5 J<,!)6(! F-"U. R9P 48O%Q4VE+D*
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MQF ;X"!;GKBRVRSSE/(L ZQA:4""!M OTP#F_=K-&W3G-1@D\XJ$6X00&HS
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M:H(APHA$1)AKL42%)9T9D7]NT$"(L(/:9RS!,B;O]PK0  _P+()H1#3%[PK
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MU(09TN#^#@0%%9+@#\;A#K[2-;>3.S5$ 6/S+:9%*3=$&%P@#:9@"K! &7X
M$81!" A!"V* %VK@"TC!!78!"[" '9) "T3!!;HI#WAA"E!!"+!L"GAA! B!
MLB2E.QO40?W""'W10Y:PBS"S!E"A!G) "VKA!_KB#\8@/SD3$:[A!VHA1+%@
M1'^ %&I@"K3@!][@!)0S!UCA#G* (!\41W/T+! 1/-TBB(;(0W;A",;A$#J
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MD:,6=%QSQQ=U<A*!9;6\H04I["6(2E%)B"+0(4F<@P4AP@C!BT"0G!"#**Q
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M7(,W.60',U0@"V;)P@6<"*@6OG#50Q!B4)Z[JC*LJ0W>G>"=UAR(P @W.MX
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MYX *G& )AS .T,I5 Z%>SW6LK*#^%)& 4*2 K"PDK--:"[M:<J(0#<IV#<2
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MHHP!RJA_[.#%.=35N Y=;EO,L,0N1L0IX CC,^/XD%688;5HG(L@4!*&)?X
M.HE4ZAJHRHCC'-? <=S-0](BGR9DU!ZK$2I5T5#809@ABSQLRFV[8 7O(D&*
M73QJ>6F(Q@X/0HA%(2*&Y-)APF+80W)!QBG;0@@G_,*B.V0JA+!!WVTTUA"K
M=(,8RO!*B60A&5'\Z23=&)-*-I7^)<:L,'P=ZI\R:N2UZ[C/D8^$9"1I@HH
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MI.N1XF?^[5]^P.S]ND@U#7A\[B?_\E<V->6/^BD X#?_]G?_JP6V4Z>+88,
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ML((G89WZN)H(Z54X#00QY %91<(W78XLP)%UK9\T*8,E4%*!*=*/X1QG95Z
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M0%CF;BF7+!@S+^SG3R&/2<4Q7MD9*L_P0D 8)&-!RO8N9W3#$1SO)&\%*E2
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M9RM"@R>"IRORA05'1Q2L0U/@A$1LIC.ZPB\@A?5000>C8R=:T*4@91<J*'A
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M+(-A>%;^B(!2"RHC:K RB-_69;<S=/'%"G-B@+B7!U*V"X<@BVRD":2P"]$
M9^R ;]K'$D(X@ R""I8 "5?X8I:0B^9GC;G("P)7BZTGA;*XB[WX;< HC.Q
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2S,$=[,$?#,(A+,(CG+\! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g89922bgi002.gif
<DESCRIPTION>G89922BGI002.GIF
<TEXT>
begin 644 g89922bgi002.gif
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M<7)R<G-S<W1T='5U=79V=G=W=WAX>'EY>7IZ>GM[>WQ\?'U]?7Y^?G]_?X"
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M^/GY^?KZ^OO[^_S\_/W]_?[^_O___P
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MT,6![.*-\O@""UHI2SYT<1VI.,,D^/ (>8Q#$USXHSR4\09E^"$7RHCD&5*
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M6,<CS*"%#B@#&Q68 1<ZX 1GT"$&&, #_K0P SHX01DQB)\F<C!=$+0B%3K
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M4<I0/JD0-A,M/6+3-6]P0-,S#?4+-\A96^B0X*FP#L+0Q+$&"J"0?@5H4E_
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M!F=PH;W)A09R!KWSAEG<P%:DIO!1GNE8!U 8CRE2':7XG;@0AB6Q"OA!#&Q
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M:ZREW/O^C 8P S/^ B3/A0Y@ 8AX ^L TQ+H@!C0%KUF ?C)@;5=A A( 2<
M@2!@"\IUYC/PC#;(<9"@\D;!!O5<DBY?AR3H@(4%B5TX;<25;C]( !7O\9T(
M F.8@1@8AR[_JO2M;L%H7XK.@=(&9S[H@%:0!="^'_,\[*+\Z/HP!,1>AR#0
M C/8VI"X4C/X L&U7)OE@LT& 6W)!59/]0G7B1R(@'$Q +@(VACX@B_(@08@
M$)LM G->$E^/BUA/(SJX]=BN .6U"&P?<VVI06 ( @QH.[KX@@H@F5''!F>(
M@#>8[5;^J  K^"KXE6[ )=O9A2J]C@%L^&\G^/=AM_=<8 &03N#%Z&\[2GCA
M:&;Z-0-G/P/V3H'0GHO%/8.9=NV8//A5-_:+T(%_9V8$7X<W* $NF/C65FJ,
MQVP0R'B0F%O\0(<S2('<R.I-9GENGFL07 \0N%AN\$F0X(,22.N0_PTZR &
M_I-XCB&9046KNM]-)M_]M2H>5UZ]KNW[$5^MK/>2[X!#N>FT> ,,.!1TL +!
M]:04&&L!S/2%I-Q@,?N:SH^NWP4F=P7=X09L8.K?\(,&8)T*0 C^$'A2B@!*
M6H\(X((Z$1)N2((4> 17V/7&V.T<4-_#3XYQ..TD$)Y%D(7^:7A\4= !%M"5
MG)OKG2V>O7<0,'UI@V'9,RB<1QA;^IXJ:P9@SA'@$6XJ;"@"UPT-%FB[70 !
M\P"&&<CI1<" Q? &+<B!4SKURVG/KTB!T3.$K_^@$H#J1(^!!AK^G*[[MF;9
M3."&(OAWX7!V/F"!F35U/P %&6_D%#C/3#\;/M"!$G ".H T%DB"O5E_J"X2
M.LCT)  (8,K,L(@1))<\8RRLR&O8D$X*3=R*Q,#6D ^((!;EY6IC)06+2:!*
MM'%H\B3*E"I7LFSI\B7,F#)GTJQI\Z;#5@9F3,,I<U$'#(M\$BUJ]"C2I$IK
M8L.V3IZW:>CDK9O&31XZJU"GC6O^R&W:NJA=&V+C^O6IPW%:3V;UYO!LPZI7
MJTZK*U5>V;C3L,%U&)5;6[9VZZ*5]]7MR:9IIR%^RUCO8WF:<L@Z&76JXH9J
M-RZVJ+;QTM"B1Y,N?=15!8VFY64" 2+3ZMBR9].N;?MV;&_."N/N[?LW\)F9
M2J3H:7I1@P1#@S-O[OPY].C2IU.O/E-4 IZK%U6H8,@Z^/#BQY,O;_Z\;%<1
M=' F/;P$;/3RY].O;_\^?M.@4L0P7AIY!,OE-Z!T98TE&C:@I&)97:!]!99-
M<BTUCBR93&525D[=)$PFPIADS"0>NH2.**(<B%6))Q*X(GF:-,""?Z09TD $
MW[%X(W#^"L5@HVBR@%#$A0VUP0((?* U31 LE+#+3.BXM0L+3O!6%)(LZ! C
M,%_P9PAB8<F$1P(\RF-( GB\- T+,)J$IIHXNFF=+ FPMUHF*<#W)IZU:6*G
M$RHFY0P+9IST!G$Y&#<)<2P@%),K7X "U2,+)B5*"6]X$^0T3LR@H"@-[?+%
M(S*U<:=#PY7DTCA%% %:JJOF^>ISHJ1@Z&J31!!!J+#J*AHZ2>3@! @B>B.,
M,N,(XY\SNT0ES(73[-(5-L(XXY4PP%PH# 9.G-1&!$E@(*D6,<2 P:+<Y'+B
M.N:.-4T2#? !##?&*(/7+DT)<]5;SR;K)S?2.N0,'1%H(6+^0Z!$(.B_;T1@
MA3!/K6.,,5/VZZ$9#81J###&/-* &>IB*"]:W,3  K[C&(--08AYDPN^"8%5
MK#S3"//LKC4GI4D$)<0XVHQAVORS4;*DX 0H&/C1D- L?#'R)%AQ$0$718#
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M*"I2&)X)4?CGU*"@[DI._0A06,LOHM $P5 $"LZ@0QB/, 9H#),*37 ^)=,
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MK,X;RP/^X<9R)G@H#6E! ^!90VAR#G2R/ RI*QNR0X1AKDS##(C21%1G*\0
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M%Z[+& (R1Q@:"WN"WUC%PVT"'3A<AWX"Q$=$2$]"OVOBBTQB&@S,)CP<'?@
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MLN ^N6)XQE"O=E6;ZK@4?;H6Z0:3K#>H,-%^6B ,_+(F7JK^&X/&#0*&?V>
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M0*MR&MB '!UV[XHMG>$N]4:'&6[2^%P Q?3@4D;B:P9H;ICA:=,P!%RRO"!
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MP4,12"6/,^C &[1BP2[0L3,ZI$ +5F"!2181@S=HX0U=!$$1S, "B!&D%17
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M PADL8XW1  $>'!W!S0!(3XD%CK&$(T\OO S;*1@U90\0RZX$ ,^8"!T?F@
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M,J16!,)5JX)YJQB) 048>IGCG\<%DK3A32A4!).0"6:@#'S%H:&Z'YD +H_
M!<HC#,*0"SI %<#@!-,X#E;0!M-@#,9@.[ !#'Z0:3/P")J0KX: #3&P"#5D
MK)-@#+F@#,9@"$7*8ZRA Y]J#.F:"ZTP X8@KHOP%H807E)+M88E"B4K$KL
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MNQ5L#!%&&6.F:?[FUM]NO5)C'G&%,1ZGO$P((W)]\X8L6F$,=#PB;8;2A"%
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M%#C&).@ *\B!$N"A$F@#>0"%"&@4)YB!-Y@!(&(!'3B#& A$=,!%)XB17<"
M%.""$K "3L& (GB##G "IM2"WO2#=:"#%&B#&:!&I: B*S ### #-BJ!,P@"
M+:@894B!)*#)7*@ 4/"&'-#.%*@ +<. &=""$J!&8= !)_C^@B  !@FQ B>H
M@"0@#F/0@2383GZD@PCX@O>$1F[( 3J(@52+ 2O0 B< !AUX3DWH .!)@B3@
M AUHI!)P2C\( NU4F_E\ QV@ ]F9@20P ]VA Q!0A@G] BN 32/5 7Z,S;!
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M 3.JX?E$E],-@B#0A%:08^0,@HJ9!@$>4=X(1V3=HG&(@2R^G"7U5=? D"0
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$@   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
